



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : G01N 33/533, C07D 401/14 C07D 405/14, 413/14, 417/14 C07D 498/22	A1	(11) International Publication Number: WO 93/11433 (43) International Publication Date: 10 June 1993 (10.06.93)
(21) International Application Number: PCT/FI91/00373 (22) International Filing Date: 5 December 1991 (05.12.91) (71) Applicant (for all designated States except US): WALLAC OY [FI/FI]; P.O. Box 10, SF-20101 Turku (FI). (72) Inventors; and (75) Inventors/Applicants (for US only) : TAKALO, Harri [FI/FI]; Punomotie 22, SF-20360 Turku (FI). MUKKALA, Veli-Matti [FI/FI]; Suovillankatu 1 as. 6, SF-20780 Karina (FI). (74) Agent: PIRHONEN, Kari; P.O. Box 142, SF-20521 Turku (FI). (81) Designated States: DE, GB, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE).		Published <i>With international search report.</i> <i>With amended claims and statement.</i>
(54) Title: LUMINESCENT LANTHANIDE CHELATES (57) Abstract The compounds of this invention are lanthanide chelates comprising three heterocyclic rings covalently coupled to each other (either one 2,6-pyridylene and two five-membered unsaturated heterocyclic ring moieties or two 2,6-pyridylene and one five-membered unsaturated heterocyclic ring moiety) and two chelating groups so seated that they together chelate the same lanthanide ion even in aqueous solutions. Optionally these lanthanide chelates also contain a reactive group for coupling to biologically active molecules. The new chelates of our invention find applications in those areas that are classical for lanthanide chelates. Moreover, these compounds are useful as probes in time-resolved fluorescence microscopy, cytometry, multilabelling techniques and process controls in industry.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

LUMINESCENT LANTHANIDE CHELATESField of the invention

5

The invention pertains to new luminescent lanthanide chelates comprising three unsaturated heterocyclic rings covalently coupled to each other and additionally comprising two chelating groups. This structure of three heterocyclic rings is formed of one or two 2,6-pyridylene moieties and five-membered unsaturated heterocyclic rings.

The new chelates of our invention find applications in those areas that are classical for lanthanide chelates and known in the art. Moreover, these compounds are useful as probes in time-resolved fluorescence microscopy, cytometry, multilabelling techniques and process controls in industry.

20

Description of the Prior Art

In immunoassays and DNA hybridization assays time-resolved luminescence spectroscopy using lanthanide chelates is well known (e.g. I.A.Hemmilä, "Applications of Fluorescence in Immunoassays" in J.D.Winefordner and I.M.Kolthoff, Eds., Chemical Analysis, Vol 117, John Wiley & Sons, Inc., USA, 1991 and the references therein). Stable luminescent lanthanide chelates also have other applications, e.g. fluorescence microscopy and cytometry. Because of their paramagnetic properties, these lanthanide chelates are useful as sensitive probes in magnetic resonance imaging (MRI). The radioactive isotopes of the metals such as indium and stable chelating ligands on the macromolecules

offer possibilities to use ligands of this invention in the treatment of diseases such as cancer.

Luminescent lanthanide chelates have previously been suggested [macropolycycles: French Patent No. 2,570,703 (1986) and Eur. Patent Appl. 321,353 (1988); phenols: U.S. Patent 4,670,572 (1987); coumarines: U.S. Patent 4,801,722 (1989) and U.S. Patent 4,794,191 (1988); polypyridines: U.S. Patent 4,837,169 (1989), U.S. Patent 4,859,777 (1989), Int. Pat. Appl. PCT/SE89/00073 (1989) and Int. Pat. Appl. PCT/SE89/00379 (1989); aryl pyridines: U.S. Pat. 4,761,481 (1988) and Int. Pat. Appl. PCT/WO89/04826; ethynyl pyridines: U.S. Patent 4,920,195 (1990); phenanthrolines: U.S. Pat. 4,772,563 (1988); salicylates: M.P.Bailey, B.F.Rocks and C.Riley, *Analyst*, **109**, 1449 (1984)].

Stable luminescent lanthanide chelates, whose energy absorbing group is either one 2,6-pyridylene and two five-membered unsaturated heterocyclic ring moieties, or two 2,6-pyridylene moieties and one five-membered unsaturated heterocyclic ring moiety coupled to each other with a covalent bond between carbon atoms, are not known. Some basic structures comprising three heterocyclic rings covalently coupled to each other (including one or two pyridine rings) have been synthesized (see e.g. V. Nair and K.H. Kim, *J. Heterocyclic Chem.* **13** (1976), 873; S. Kubota and H. Ohtsuka, *Tokushima Daigaku Yakugaku Kenkyu Nempo* **9** (1963) 15, CA58:2449a; J.F. Geldhard and F. Lions, *J. Org. Chem.* **30** (1965) 318; R. Menasse, G. Klein and H. Erlenmeyer, *Helv. Chim. Acta*, **38** (1955) 1289; H.A. Goodwin, *Aust. J. Chem* **17** (1964) 1366; R.J. Clark and J. Walker, *J. Chem. Soc.C* **6** (1966) 1354; S. Gronowitz and D. Peters, *Heterocycles* **30(1)** (1990) 645 and A.T. Parker, P. Singh and V. Vignevich, *Aust. J. Chem.* **44** (1991) 1041). As such these

compounds are not stable enough for use with lanthanide ions in aqueous solution. A lanthanide chelate, containing one 2,6-pyridylene and two 1,3-pyrazolylylene groups having a covalent bond between the carbon and nitrogen atoms, has
5 been synthesized (M. Alanso, J. de Mendoza, M. Remuiñan, H. Roman and J.C. Rodriguez-Ubis, *2nd Conference on Methods and Applications of Fluorescence Spectroscopy*, Graz, Austria, 14-17.10.1991, P1/25). The luminescence properties of this chelate have not been published. The chelate has
10 no group for coupling to biologically active material and it cannot be used as such for applications mentioned in this invention.


The invention

15

The compounds of this invention are lanthanide chelates comprising three heterocyclic rings covalently coupled to each other (either one 2,6-pyridylene and two five-membered unsaturated heterocyclic ring moieties or two 2,6-pyridy-
20 lene and one five-membered unsaturated heterocyclic ring moiety) and two chelating groups so seated that they together chelate the same lanthanide ion even in aqueous solutions. Optionally these lanthanide chelates also contain a reactive group for coupling to biologically
25 active molecules.

The compounds of the invention are lanthanide chelates consisting of a lanthanide ion and a chelator having a common structure shown in Formula I.

30




Formula I

The acid, ordinary salts and ester forms of Formula I are also novel and notable.



In Formula I, ~ represents a covalent bond between two carbon atoms and - represents a covalent bond.

E represents methylene (CH_2) or carbonyl (C=O).


One or two of $[\text{A}_1]$, $[\text{B}]$ and $[\text{A}_2]$ in a $[\text{A}_1]-[\text{B}]-[\text{A}_2]$ structure represent a bivalent five-membered unsaturated heterocyclic ring. Each of the remaining of $[\text{A}_1]$, $[\text{B}]$ and $[\text{A}_2]$ is 2,6-pyridylene. Preferably either $[\text{A}_1]$ and $[\text{A}_2]$ or $[\text{B}]$ are 2,6-pyridylenes. The heteroatoms in five-membered unsaturated heterocyclic rings are selected from the group consisting of nitrogen, sulphur or oxygen. One heteroatom in each ring is coordinating to the same lanthanide ion so that two five-membered rings are formed in which one member is the lanthanide ion and two members are coordinating heteroatoms of different rings $[\text{A}_1]$, $[\text{B}]$ and $[\text{A}_2]$. Examples of preferable five-membered unsaturated heterocyclic bivalent groups include:




25




30




3-thiazolin-2,4-ylene:



2,4-oxazolylene:




2-oxazolin-2,4-ylene:




10

3-oxazolin-2,4-ylene:




2,4-imidazolylene:




15

2-imidazolin-2,4-ylene:




3-imidazolin-2,4-ylene:




20

1,2,4-triazol-3,5-ylene:




25

1,3,4-oxadiazol-2,5-ylene:




1,2,4-oxadiazol-3,5-ylene:




30

1,3-pyrazolylene:



or

2,5-pyrrolylene:



In 2,6-pyridylenes and in five-membered unsaturated heterocyclic bivalent rings one hydrogen can be replaced with the appropriate group G_1 , G_2 and G_3 .

- 5 The substituents G_1 , G_2 and G_3 can be selected from the group consisting of hydroxy, nitro, amino or lower alkyl substituted amino, lower aryl substituted amino or lower acyl substituted amino, alkyl, aryl, alkylaryl, arylalkyl, arylethynyl, such as phenylethynyl, alkoxy or aryloxy
- 10 groups with the proviso alkyls contain 1-12 carbon atoms and aryls are selected from phenyl, naphthyl and pyridyl. G_1 , G_2 and G_3 can also be a group containing aryl (selected from phenyl, naphthyl and pyridyl) and alkylene parts which contains from 1 to 8 carbon atoms and additionally from 0
- 15 to 4 other atoms such as oxygen, sulphur, nitrogen or phosphorus. Each of the above mentioned groups optionally contains amino, aminooxy, carboxyl, hydroxy, aldehyde or mercapto groups or an activated form made from them, such as isothiocyanato, isocyanato, diazonium, bromoacetamido,
- 20 iodoacetamido, reactive esters (such as N-hydroxysuccinimide, 4-nitrophenyl and 2,4-dinitrophenyl esters), pyridyl-2-dithio, 4-chloro-6-ethoxytriazon-2-ylamino or 4,6-dichlorotriazon-2-ylamino. Other examples of suitable groups to be used in the labelling of compounds exhibiting
- 25 biological affinity are presented e.g. in R.F.Steiner and I.Weinryb (eds.), "Excited States of Proteins and Nucleic Acids", Basingstoke Corp., London, 1971. One or two of the substituents G_1 , G_2 and G_3 can also be attached to a compound exhibiting biospecific affinity. Such molecules
- 30 include e.g. proteins (such as enzymes), antibodies, antigens (haptens), oligo- and polynucleotides, lectins, receptors, carbohydrate structures (such as dextrans), protein A, IgG, drugs etc. This type of biologically active compounds are often called target substances (target

molecules). The binding is performed in such a way that these molecules still retain their biospecific affinity.

Ch₁ and Ch₂ represent identical or different chelating groups, possibly linked together. Each of these chelating groups comprises at least two heteroatoms that are coordinated to the lanthanide ion and are selected from the group consisting of oxygen and nitrogen. At least one of the said coordinating heteroatoms in each of Ch₁ and Ch₂ is forming a five- or six-membered ring together with the lanthanide ion and a coordinating heteroatom of one of [A₁], [B] and [A₂]. The distance between each pair of heteroatoms participating in the chelation and forming the same five- or six-membered ring is two or three atoms, respectively.

15

Examples of efficient chelating heteroatoms include amino nitrogens (primary, secondary and tertiary amine) and negatively charged oxygens (carboxylate anions, enolate anions, phosphates and phosphonates). In most cases the bridge between the chelating heteroatoms contains 1, 2 or 3 saturated carbon atoms. Among particularly important Ch₁ and Ch₂ structures are N,N-bis(carboxymethyl)amino [-N(CH₂COO⁻)₂], N,N-bis(carboxyethyl)amino [-N(CH₂CH₂COO⁻)₂], analogous phosphates [e.g. -N(CH₂-O-PO₃²⁻)₂] and phosphonates [e.g. -N(CH₂-PO₃²⁻)₂] and 2,6-dicarboxypiperidin-1-yl. Alternatively, Ch₁ and Ch₂ may form one or two bridges that covalently connect the two outer heterocyclic rings ([A₁] and [A₂]) giving a macrocyclic chelating compound. The bridge/bridges consist of saturated carbon, oxygen or nitrogen atoms. The nitrogens and the oxygens are selected from secondary or tertiary amino nitrogens and ether oxygens. Preferably such a bridge together with the E-[A₁]-[B]-[A₂]-E system forms a carboxymethylated azacrown [the bridge is e.g. -N(CH₂COO⁻)CH₂CH₂N(CH₂COO⁻)- or

30

-N(CH₂COO⁻)-], a cryptate [the bridge is e.g. -N(CH₂CH₂-O-CH₂CH₂-O-CH₂CH₂)₂N-] or a crown ether (the bridge is e.g. -O-CH₂CH₂-O-CH₂CH₂-O- or -O-CH₂CH₂-O-).

- 5 In some compounds of the invention the chelating heteroatoms (nitrogen and oxygen) may exist as the corresponding protonated forms and for oxygen also as ester forms, such as lower alkyl (C₁-C₆), benzyl or tert-butyl esters.
- 10 From a spectrofluorometric point of view the interesting chelate forms are such molecules where Ch₁ and Ch₂ together with E-[A₁]-[B]-[A₂]-E structure are chelated to the lanthanide ion, preferably to Eu³⁺, Tb³⁺, Dy³⁺ or Sm³⁺. These ligands can also be suitable for chelating such metal ions
- 15 as Ru²⁺, Os³⁺, Ir³⁺ and Rh³⁺. As strong chelate forming compounds they are potential chelators also for radioactive isotopes of different metals to be used in applications classical for radiotracers.
- 20 The new chelates of our invention find applications in the areas that are classical for lanthanide chelates. Moreover, these compounds are useful as probes in time-resolved fluorescence microscopy, cytometry, nucleic acid sequencing, nucleic acid and protein finger printing, homogeneous
- 25 hybridization assays for nucleic acid detection, homogeneous fluorometric immunoassays, multilabelling techniques and process controls in industry.

Contrary to the many previously mentioned patents, full

30 coordination number nine can easily be achieved with the new lanthanide chelates of this invention. This implies that there are no water molecules coordinated to the lanthanide ion. The quenching effect of water is thus minimized and the decay time of the luminescence is in its

- maximum. Thus the long-lived and very intensive luminescence of the lanthanide chelates can be effectively determined after the short-lived background has decayed. In e.g. microscopic applications and process controls in industry
- 5 very stable (photo, thermodynamic and kinetic stability) chelates are needed. As compared to the other known lanthanide chelate structures, these stability requirements are best fulfilled with the chelates of this invention.
- 10 The smaller size of unsaturated five-membered heterocycles compared to e.g. pyridine and phenol makes the ligands of this invention more flexible. This means that lanthanide ion is better crowded with the chelator and the pi-electrons of [A₁], [B] and [A₂] and the free electron pairs of
- 15 their heteroatoms are better delocalized over [A₁]-[B]-[A₂].

The basicity of some five-membered unsaturated heterocycles (e.g. pK_a for pyridine is 5.25 and for imidazole 6.953)

20 makes them better chelators than pyridine. Moreover, in some of the chelates the aromatic structure is negatively charged (e.g. compounds containing 1,2,4-triazol-3,5-ylene). Besides that this stabilizes chelates, it additionally changes their adsorption properties diminishing

25 unspecific binding to column materials and plastics.

It is known that C-H stretchings of the ligand decrease the luminescence intensity of the lanthanide chelates. The number of C-H bonds in the chelates of this invention has

30 been reduced by five-membered heterocyclic ring moieties compared to pyridines and phenols.

As compared to the other lanthanide chelates these new structures of this invention exhibit a greater extinction

coefficient, longer excitation wavelengths and better energy transfer from the ligand to the lanthanide ion, which lead to improvements in the detection sensitivity of the luminescent labels.

5

The structures and the synthetic routes employed in the experimental part are shown in reaction schemes 1-14. The compounds 42 (Scheme 7), 57a and 57b (Scheme 9), 68 (Scheme 10) and 80 are examples of compounds capable of binding to biologically active molecules. The other schemes represent the synthesis of potential structures which can easily be modified to such compounds with known methods. E.g. compound 32, the corresponding 2,6-dicyanopyridine derivative and analogous compounds having a longer chain between the pyridine and the benzene rings can be used as a versatile starting material for chelates that can be coupled to compounds exhibiting biological affinity. In Example 84 compound 68 has been used for labelling of antibody. In Example 86 terbium(III) labelled antibody has been used for time-resolved fluorescence immunoassay and microscopy.

Modified iminodiacetic acid ester can be used instead of unsubstituted iminodiacetic acid ester as is taught in Int. Pat. Appl. PCT/SE89/00379 (1989).

25

General methods for the preparation of unsaturated five-membered heterocycles are skill of art (see prior art and e.g. A.R.Katritzky, "Handbook of Heterocyclic Chemistry", Pergamon Press, Great Britain, 1986).

30

The synthesis of phosphonic acids can be made using methods described in the literature, see e.g. E.K. Fields, J. Am. Chem. Soc. 74 (1952) 1525; G.R. Newkome, G.E. Kiefer, N.

Matsumura and W.E. Puckett, *J. Org. Chem.* **50** (1985) 3807.


The new chelates of our invention can be used in time-resolved fluorescence immunoassays, DNA hybridization
5 assays and microscopy analogously to the methods described in the literature, see e.g. I.A. Hemmilä, "Applications of Fluorescence in Immunoassays" in J.D. Winefordner and I.M. Kolthoff, Eds., *Chemical Analysis*, Vol 117, John Wiley & Sons, Inc., USA, 1991 and the references therein.

10

The method for the determination of an analyte in a sample comprises three steps: (a) contacting the sample with a reactant exhibiting biospecific affinity towards the analyte to the formation of a complex comprising said
15 analyte and said reactant, the condition and amounts of reactants being selected so that the amount of complex formed is a function of the amount of analyte in the sample, (b) quantitatively or qualitatively measuring the amount of complex formed by the use of a reactant that
20 exhibits biospecific affinity for said complex and being labelled with an analytically detectable group and (c) relating the measured amount of the complex to the amount of analyte in the sample. The reactant labelled with the analytically detectable group complies with a lanthanide
25 chelate according to this invention.

Example 1. The synthesis of 2,6-bis(5'-[N,N-bis(methoxycarbonylmethyl)aminomethyl]-2'-furyl)-4-(2",4",6"-trimethoxyphenyl)pyridine (1).
30

A mixture of 2,6-bis(2'-furyl)-4-(2",4",6"-trimethoxyphenyl)pyridine (0.050 g, 0.13 mmol), dimethyl iminodiacetate (0.050 g, 0.32 mmol), 37 % formaline (24 µl, 0.32 mmol) and



Scheme 1 The synthesis of compound 2

acetic acid (1 ml) was stirred for five hours at 110°C. After evaporation the residue was dissolved in dichloromethane, extracted with water and dried with sodium sulfate. The product was purified with flash chromatography (silica, chloroform). The yield was 11 mg (12 %).

¹H NMR (60 MHz, CDCl₃): 3.60 (8 H, s); 3.67 (12 H, s); 3.74 (6 H, s); 3.88 (3 H, s); 4.03 (4 H, s); 6.24 (2 H, s); 6.39 (2 H, d, J = 3 Hz); 7.06 (2 H, d, J = 3 Hz); 7.50 (2 H, s)
UV (λ_{max} in ethanol): 331 & 284 nm

10

Example 2. The synthesis of 2,6-bis{5'-[N,N-bis(carboxymethyl)aminomethyl]-2'-furyl}-4-(2'',4'',6''-trimethoxyphenyl)pyridine (2).

15 A mixture of compound 1 (11 mg, 15 μmol) and 0.5 M potassium hydroxide in ethanol (1 ml) was stirred for two hours. The solution was neutralized with 1 M hydrochloric acid and evaporated to dryness. The residue was dissolved in water (0.5 ml).

20 UV (λ_{max} in water as free ligand): 331 & 283 nm
UV (λ_{max} in water as europium chelate): 338, 300 & 290 nm

Example 3. The synthesis of 2,6-bis(4'-carboxy-2'-thiazolin-2'-yl)pyridine (3).

25

L-Cysteine (0.66 g, 5.4 mmol) was dissolved in water (5 ml) and the solution was neutralized with sodium bicarbonate. A mixture of 2,6-dicyanopyridine (0.24 g, 1.9 mmol) in methanol (5 ml) was added to the solution of L-cysteine. After evaporation of methanol the crystallized product was filtered and washed with acetone. The yield was 0.35 g (55 %).


30

¹H NMR (60 MHz, D₂O): 3.23-3.85 (4 H, m); 5.20 (2 H, t, J = 9 Hz); 8.05-8.35 (3 H, m)

UV (λ_{max} in water as free ligand): 288 nm

35 UV (λ_{max} in water as europium(III) chelate): 295 & 240 nm


5



L-Cysteine



10



3

15

1. SOCl_2
2. $\text{HN}(\text{CH}_2\text{COO-tert-Bu})_2$

 CF_3COOH


20



4



25



5

30

35 Scheme 1 The synthesis of compound 5

Example 4. The synthesis of 2,6-bis(4'-[N,N-bis(tert-butoxy-carbonylmethyl)aminocarbonyl]-2'-thiazolyl)pyridine (4).

A mixture of compound 3 (0.35 g, 1.0 mmol) and thionyl chloride (5 ml) was refluxed for one hour. After evaporation to dryness the residue was dissolved in dry pyridine (6 ml), di-tert-butyl iminodiacetate (0.64 g, 2.6 mmol) was added and the solution was refluxed for two hours. The solution was evaporated, dissolved in chloroform and filtered. The product was purified with flash chromatography (silica, chloroform).
¹H NMR (60 MHz, CDCl₃): 1.45 (18 H, s); 1.51 (18 H, s); 4.26 (4 H, s); 4.63 (4 H, s); 7.86-8.27 (3 H, m); 8.33 (2 H, s)
UV (λ_{max} in ethanol): 326 & 289 nm; mol wt (MS): 787 (M⁺)

Example 5. The synthesis of 2,6-bis(4'-[N,N-bis(carboxymethyl)aminocarbonyl]-2'-thiazolyl)pyridine (5).

A solution of compound 4 in trifluoroacetic acid was kept at room temperature overnight. After evaporation the residue was triturated with diethyl ether and filtered.

¹H NMR (60 MHz, DMSO-d₆): 4.21 (4 H, s); 4.57 (4 H, s); 8.10-8.30 (3 H, m); 8.50 (2 H, s)


UV (λ_{max} in water as free ligand): 325 & 278 nm

UV (λ_{max} in water as europium(III) chelate): 325 & 278 nm


Example 6. The synthesis of 2,6-bis(5'-methyl-4'-phenyl-thiazol-2'-yl)pyridine (6).

A mixture of 2,6-pyridinedithiodicarboxamide (0.76 g, 3.9 mmol), 2-bromo-1-phenyl-1-propanone (1.8 g, 8.4 mmol), ethanol (14 ml) and N,N-dimethylformamide (5 ml) was refluxed for 8.5 hours. Solid material was filtered and washed with ethanol. The suspension of the hydrobromic salt of the product in hot water (40 ml) was alkalized with 20 g sodium bicarbonate

5




10




15

20




25

30



8

35



Scheme 3. The synthesis of compound 9

15

solution. The product was filtered and washed with water. The yield was 1.35 g (81 %). M.p. 273°C.

20 ¹H NMR (400 MHz, CDCl₃): 2.67 (6 H, s); 7.36-7.40 (2 H, m); 7.47-7.50 (4 H, m); 7.74-7.76 (4 H, m); 7.86 (1 H, t, J = 7.7 Hz); 8.21 (2 H, d, J = 7.7 Hz)

UV (λ_{max} in acetonitrile): 342 & 238 nm

25 Example 7. The synthesis of 2,6-bis(5'-bromomethyl-4'-phenylthiazol-2'-yl)pyridine (7).

A mixture of compound 6 (0.50 g, 1.2 mmol), N-bromosuccinimide (0.42 g, 2.4 mmol), α,α'-azoisobutyronitrile (21 mg, 0.13 mmol) and benzene (140 ml) was refluxed for six hours. The reaction mixture was evaporated and the product was purified with flash chromatography (silica, dichloromethane). The yield was 0.10 g (15 %). M.p. 223°C.

35 ¹H NMR (400 MHz, CDCl₃): 4.88 (4 H, s); 7.45-7.48 (2 H, m); 7.52-7.56 (4 H, m); 7.82-7.85 (4 H, m); 7.91 (1 H, t, J = 7.9

Hz); 8.29 (2 H, d, $J = 7.8$ Hz)

UV (λ_{\max} in ethanol): 340, 316 & 243 nm

Example 8. The synthesis of 2,6-bis{5'-[N,N-bis(tert-butoxy-
5 carbonylmethyl)aminomethyl]-4'-phenylthiazol-2'-yl}-
pyridine (8).

A mixture of compound 7 (90 mg, 0.15 mmol), di-tert-butyl
iminodiacetate (76 mg, 0.31 mmol), dry potassium carbonate
10 (0.21 g, 1.5 mmol) and dry acetonitrile (30 ml) was refluxed
for six hours. The reaction mixture was filtered and the
filtrate was evaporated to dryness. The residue was dissolved
in chloroform (5ml), washed with water (2 x 2 ml) and dried
with sodium sulfate. Evaporation left a pure product. The
15 yield was 0.14 g (100 %). M.p. 121-123°C.

^1H NMR (400 MHz, CDCl_3): 1.43 (36 H, s); 3.54 (8 H, s); 4.30
(4 H, s); 7.35-7.39 (2 H, m); 7.44-7.47 (4 H, m); 7.72-7.74
(4 H, m); 7.86 (1 H, t, $J = 7.8$ Hz); 8.26 (2 H, d, $J = 7.8$ Hz)
UV (λ_{\max} in ethanol): 340, 312 & 239 nm

20

Example 9. The synthesis of 2,6-bis{5'-[N,N-bis(carboxy-
methyl)aminomethyl]-4'-phenylthiazol-2'-yl}-pyridine (9).

A solution of compound 8 (100 mg, 0.11 mmol) in trifluoro-
25 acetic acid (2 ml) was kept 1.5 hours at room temperature.
After evaporation the residue was triturated with diethyl
ether and filtered. The yield was 30 mg (40 %). M.p. 185°C
(dec.).


^1H NMR (400 MHz, $\text{DMSO}-d_6$): 3.56 (8 H, s); 4.29 (4 H, s); 7.42-
30 7.45 (2 H, m); 7.49-7.53 (4 H, m); 7.72-7.74 (4 H, m); 8.13
(1 H, t, $J = 7.9$ Hz); 8.26 (2 H, d, $J = 7.9$ Hz)


UV (λ_{\max} in water as free ligand): 340, 305 & 237 nm

UV (λ_{\max} in water as europium(III) chelate): 350, 310 & 240 nm

35

19





35 Scheme 4. The synthesis of compounds 14 and 16

Example 10. The synthesis of 2,6-bis[N-(1'-phenyl-1'-propanon-2'-yl)aminocarbonyl]pyridine (10).

2-Amino-1-phenyl-1-propanone hydrochloride (1.93 g, 10.3 mmol)
5 was added in small portions to a mixture of 2,6-pyridine-dicarbonyl dichloride (1.05 g, 5.20 mmol) and pyridine (25 ml). After refluxing for 15 min the reaction mixture was evaporated to dryness. The residue was dissolved in chloroform (50 ml), washed with saturated sodium bicarbonate (20 ml) and
10 dried with sodium sulfate. The product was purified with flash chromatography (silica, petroleum ether/ethyl acetate, 1/1). The yield was 1.60 g (72 %). M.p. 71°C.

¹H NMR (400 MHz, CDCl₃): 1.65 (3 H, d, J = 7.3 Hz); 1.66 (3 H, d, J = 7.3 Hz); 5.79 (1 H, quintet, J = 7.3 Hz); 5.80 (1 H,
15 quintet, J = 7.3 Hz); 7.55 (4 H, t, J = 7.4 Hz); 7.65 (2 H, t, J = 7.4 Hz); 8.06 (1 H, t, J = 7.8 Hz); 8.11-8.14 (4 H, m); 8.39 (1 H, d, J = 7.8 Hz); 8.39 (1 H, d, J = 7.8 Hz); 8.94 (1 H, d, J = 7.3 Hz); 9.02 (1 H, d, J = 7.3 Hz)

UV (λ_{max} in ethanol): 244 nm

20

Example 11. The synthesis of 2,6-bis(4'-methyl-5'-phenyl-oxazol-2'-yl)pyridine (11).

A mixture of compound 10 (1.56 g, 3.65 mmol) and phosphorus
25 oxychloride (55 ml) was refluxed for 23 hours. After evaporation to dryness the residue was treated with water and the mixture was neutralized with 1 M sodium hydroxide. The crude product was filtered, washed with water and finally purified with flash chromatography (silica, 5% methanol in chloroform).

30 The yield was 1.26 g (88 %). M.p. 161-163°C.

¹H NMR (400 MHz, CDCl₃): 2.56 (6 H, s); 7.37 (2 H, t, J = 7.6 Hz); 7.49 (4 H, t, J = 7.6 Hz); 7.80 (4 H, d, J = 7.6 Hz); 7.95 (1 H, t, J = 8.0 Hz); 8.20 (2 H, d, J = 8.0 Hz)

UV (λ_{max} in ethanol): 350, 295, 260 & 220(sh) nm

35

Example 12. The synthesis of 2,6-bis(4'-bromomethyl-5'-phenyloxazol-2'-yl)pyridine (12).

A mixture of compound 11 (0.63 g, 1.6 mmol), N-bromo-succinimide (0.57 g, 3.2 mmol), α,α' -azoisobutyronitrile (29 mg, 0.18 mmol) and carbon tetrachloride (10 ml) was refluxed for three hours. After evaporation the solid material was washed several times with a mixture of petroleum ether and ethyl acetate (5/3). The yield was 0.44 g (50 %). M.p. 234-237°C.

^1H NMR (400 MHz, CDCl_3): 4.71 (4 H, s); 7.46 (2 H, t, $J = 7.3$ Hz); 7.55 (4 H, t, $J = 7.3$ Hz); 7.88 (4 H, d, $J = 7.3$ Hz); 8.00 (1 H, t, $J = 7.9$ Hz); 8.28 (2 H, d, $J = 7.9$ Hz)

UV (λ_{max} in ethanol): 353, 293 & 262 nm

Example 13. The synthesis of 2,6-bis[4'-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-5'-phenyloxazol-2'-yl]pyridine (13).

A mixture of compound 12 (0.28 g, 0.50 mmol), di-tert-butyl iminodiacetate (0.25 g, 1.0 mmol), dry potassium carbonate (0.69 g, 5.0 mmol) and dry acetonitrile (50 ml) was refluxed overnight. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was dissolved in chloroform (15 ml), washed with water (2 x 5 ml) and dried with sodium sulfate. The product was purified with flash chromatography (silica, petroleum ether/ethyl acetate, first 5/1 then 5/2). The yield of an oily product was 0.21 g (61 %).

^1H NMR (400 MHz, CDCl_3): 1.43 (36 H, s); 3.58 (8 H, s); 4.21 (4 H, s); 7.38 (2 H, t, $J = 7.6$ Hz); 7.49 (4 H, t, $J = 7.6$ Hz); 7.94 (1 H, t, $J = 7.8$ Hz); 8.01 (4 H, d, $J = 7.6$ Hz); 8.28 (2 H, d, $J = 7.8$ Hz)

UV (λ_{max} in ethanol): 335(sh), 301 & 262 nm

Example 14. The synthesis of 2,6-bis(4'-[N,N-bis(carboxymethyl)aminomethyl]-5'-phenyloxazol-2'-yl)pyridine (**14**).

A solution of compound **13** (0.21 g, 0.24 mmol) in trifluoroacetic acid (6.5 ml) was kept 1.5 hours at room temperature. After evaporation the residue was triturated with diethyl ether and filtered. The yield was 0.13g (81 %). M.p. 173°C (dec.).

¹H NMR (400 MHz, DMSO-d₆): 3.65 (8 H, s); 4.18 (4 H, s); 7.47 (2 H, t, J = 7.8 Hz); 7.56 (4 H, t, J = 7.8 Hz); 8.01 (4 H, d, J = 7.8 Hz); 8.19-8.23 (1 H, m); 8.28-8.30 (2 H, m)

UV (λ_{max} in water as free ligand): 332, 310 & 259 nm

UV (λ_{max} in water as europium(III) chelate): 350 & 243 nm

Example 15. The synthesis of 2,6-pyridinedicarboxyamidine dihydrochloride (**15**).

A mixture of 2,6-dicyanopyridine (7.0 g, 54 mmol), sodium methoxide (0.59 g, 11 mmol) and methanol (50 ml) was stirred for 2.5 hours at room temperature. Ammonium chloride (5.9 g, 110 mmol) was added and the reaction mixture was stirred for three days. The product was filtered and washed with diethyl ether. The yield was 12.0 g (94%). M.p. >310°C (dec.).

¹H NMR (400 MHz, D₂O): 8.32-8.49 (3 H, m)

UV (λ_{max} in water): 273 & 224 nm

Example 16. The synthesis of 2,6-bis(4'-methyl-5'-phenylimidazol-2'-yl)pyridine (**16**).

0.5 M Potassium hydroxide (17 ml) was added to a mixture of compound **15** (0.50 g, 2.1 mmol), 2-bromo-1-phenyl-1-propanone (0.89 g, 4.2 mmol), N,N-diisopropylethylamine (1.1 g, 8.4 mmol) and chloroform (10 ml). After refluxing for one day the solid material was filtered, washed with chloroform and the filtrate was evaporated to dryness. The product was purified


with flash chromatography (silica, first chloroform, then 5 % methanol in chloroform). The yield of an oily product was 0.17 g (21 %).

^1H NMR (400 MHz, CDCl_3): 2.28 (6 H, s); 7.21 (2 H, t, $J = 7.3$ Hz); 7.30 (4 H, t, $J = 7.3$ Hz); 7.49–7.52 (4 H, m); 7.67 (1 H, t, $J = 7.8$ Hz); 8.05 (2 H, d, $J = 7.8$ Hz)


UV (λ_{max} in ethanol): 353, 306 & 266 nm

mol wt (MS): 391 (M^+)

10



15



20

25

Scheme 5. The synthesis of compound 18

30

Example 17. The synthesis of 2,6-bis(1'-[N,N-bis(methoxycarbonylmethyl)aminomethyl]-3'-pyrazolyl)pyridine (17).

A mixture of 37% formaline (0.81 g, 10 mmol), methanol (40 ml) and dimethyl iminodiacetate (1.5 g, 10 mmol) was evaporated

35

to dryness. The residue was dissolved in methanol (40 ml) and evaporated once again. 2,6-Bis(3'-pyrazolyl)pyridine (1.1 g, 5.0 mmol) was added and the reaction mixture was stirred for 20 hours at 110°C. The product was purified with flash chromatography (silica, triethylamine/petroleum ether/ethyl acetate, 1/5/3). The yield was 1.54 g (55 %).

¹H NMR (60 MHz, CDCl₃): 3.67 (12 H, s); 3.67 (8 H, s); 5.20 (4 H, s); 7.06 (2 H, d, J = 2 Hz); 7.61 (2 H, d, J = 2 Hz); 7.74-8.02 (3 H, m)

mol wt (MS): 557 (M⁺)

UV (λ_{max} in ethanol): 301 & 251 nm


Example 18. The synthesis of 2,6-bis{1'-[N,N-bis(carboxymethyl)aminomethyl]-3'-pyrazolyl}pyridine (**18**).

A mixture of compound **17** (1.0 g, 1.8 mmol), 0.5 M potassium hydroxide in ethanol (50 ml) was stirred for three hours, water (0.5 ml) was added and the reaction mixture was stirred for one hour. The reaction mixture was evaporated to dryness and the residue was dissolved in water (2 ml). The solution was acidified with 2 M hydrochloric acid and triturated with ethanol. The solid material was filtered, washed with ethanol and the filtrate was evaporated to dryness. The product was purified with flash chromatography (silica, acetonitrile/water, 4/1). After evaporation the product was crystallized from water. The yield was 0.19 g (21%).


¹H NMR (60 MHz, DMSO-d₆): 3.64 (8 H, s); 5.46 (4 H, s); 6.97-7.05 (2 H, m); 7.75-7.92 (5 H, m)

UV (λ_{max} in water as free ligand): 301 & 234 nm


UV (λ_{max} in water as europium(III) chelate): 313, 263, 254 & 234 nm




10




20



30





Scheme 5. The synthesis of compounds 23, 30 and 39

Example 19. The synthesis of 2,4-di(2'-pyridyl)thiazole N',N'-dioxide (19).

m-Chloroperbenzoic acid (50-55 %, 25.9 g, about 75 mmol) was added in small portions during 24 hours to a mixture of 2,4-di(2'-pyridyl)thiazole (2.39 g, 10.0 mmol) and dichloromethane (400 ml). After stirring for 24 hours, the reaction mixture was washed with 10 % sodium carbonate (3 x 150 ml) and water (150 ml). The combined water fractions were extracted with chloroform (150 ml). The combined organic fractions were dried with sodium sulfate and evaporated to dryness. The yield was 2.71 g (100 %).

¹H NMR (60 MHz, CDCl₃): 7.18-7.66 (4 H, m); 7.87-8.04 (1 H, m); 8.35-8.76 (3 H, m); 9.53 (1 H, s)

mol wt (MS): 271 (M⁺)

UV (λ_{max} in ethanol): 324 & 249 nm

Example 20. The synthesis of 2,4-bis(6'-cyano-2'-pyridyl)-thiazole (20).

20

Trimethylsilylcyanide (20 ml, 150 mmol) was added during five minutes to a mixture of compound 19 (2.71 g, 10.0 mmol) and dichloromethane (110 ml). After stirring for five minutes benzoyl chloride (7.2 ml, 60 mmol) was added and the reaction mixture was stirred for 9 days. After concentration to half of its original volume, 10 % potassium carbonate (300 ml) was added and the reaction mixture was stirred for half an hour. The product was filtered, washed with water and cold dichloromethane. The yield was 1.84 g (64 %).

mol wt (MS): 289 (M⁺)

UV (λ_{max} in ethanol): 301, 271 & 252 nm

35

Example 21. The synthesis of 2,4-bis(6'-aminomethyl-2'-pyridyl)thiazole pentahydrochloride (**21**).

1 M Borane in tetrahydrofuran (52 ml, 52 mmol) was added during 10 minutes to a mixture of compound **20** (1.16 g, 4.00 mmol) and dry tetrahydrofuran (50 ml). After stirring for 24 hours, the extra borane was destroyed by adding methanol. The mixture was evaporated to dryness and methanol saturated with hydrogen chloride (70 ml) was added. After stirring for one hour, the product was filtered and washed with cold methanol. The yield was 0.80 g (42 %).

¹H NMR (60 MHz, D₂O): 4.56 (2 H, s); 4.57 (2 H, s); 7.55-7.72 (2 H, m); 8.00-8.47 (4 H, m); 8.56 (1 H, s)

UV (λ_{max} in water): 320 (sh), 292 & 244 nm

15

Example 22. The synthesis of 2,4-bis{6'-bis[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2'-pyridyl}thiazole (**22**).

A mixture of compound **21** (0.48 g, 1.0 mmol), N,N-diisopropylethylamine (2.6 ml, 15 mmol), tert-butyl bromoacetate (0.78 g, 4.0 mmol) and acetonitrile (20 ml) was refluxed for 23 hours. After evaporation, the residue was dissolved in chloroform (50 ml), washed with water (3 x 20 ml) and dried with sodium sulfate. The product was purified with flash chromatography (silica, petroleum ether/ethyl acetate, 5/3.). The yield was 0.47 g (63 %).

¹H NMR (400 MHz, CDCl₃): 1.48 (18 H, s); 1.48 (18 H, s); 3.55 (8 H, s); 4.11 (2 H, s); 4.12 (2 H, s); 7.59 (1 H, d, J = 7.6 Hz); 7.71 (1 H, d, J = 7.6 Hz); 7.79 (1 H, t, J = 7.6 Hz); 7.81 (1 H, t, J = 7.6 Hz); 8.13 (1 H, d, J = 7.6 Hz); 8.18 (1 H, d, J = 7.6 Hz); 8.20 (1 H, s)

mol wt (MS): 753 (M⁺)

35

Example 23. The synthesis of 2,4-bis{6'-bis[N,N-bis(carboxymethyl)aminomethyl]-2'-pyridyl}thiazole (23).

This compound (23) was synthesized using a method analogous to the synthesis described in Example 9. The yield was 100 %.

¹H NMR (400 MHz, DMSO-d₆): 3.63 (4 H, s); 3.72 (4 H, s); 4.12 (2 H, s); 4.21 (2 H, s); 7.56 (1 H, d, J = 7.6 Hz); 7.69 (1 H, d, J = 7.6 Hz); 7.99 (1 H, t, J = 7.6 Hz); 8.03 (1 H, t, J = 7.6 Hz); 8.14 (1 H, d, J = 7.6 Hz); 8.18 (1 H, d, J = 7.6 Hz); 8.39 (1 H, s)

UV (λ_{max} in water as free ligand): 325(sh), 294 & 247 nm

UV (λ_{max} in water as europium(III) chelate): 331, 295 & 243 nm

Example 24. The synthesis of 4-phenylpyridine-2-tiocarboxamide (24).

Absolute ethanol saturated with ammonia (10 ml) was added to a cold solution of 2-cyano-4-phenylpyridine (1.8 g, 10 mmol) and absolute ethanol (30 ml). The mixture was saturated with hydrogen sulfide. After stirring overnight, the solution was concentrated to 10 ml. The cold mixture was filtered and washed with cold ethanol. The yield was 1.69 g (79 %).

¹H NMR (60 MHz, CDCl₃): 7.69-7.94 (6 H, m); 8.83 (1 H, d, J = 5 Hz); 9.24 (1 H, d, J = 2 Hz)

UV (λ_{max} in ethanol): 322 & 241 nm

Example 25. The synthesis of 2-(4'-phenyl-2'-pyridyl)-4-(2''-pyridyl)thiazole (25).

A mixture of compound 24 (1.07 g, 5.00 mmol), 2-(bromoacetyl)-pyridine (1.00 g, 5.00 mmol) and ethanol (20 ml) was refluxed for three hours. A cold mixture was filtered and washed with cold ethanol. The suspension of the hydrobromic salt of the product in hot water (40 ml) was alkalized with solid sodium carbonate. The product was filtered and washed with cold

water. The yield was 1.25 g (79 %).

¹H NMR (400 MHz, CDCl₃): 7.25-7.29 (1 H, m); 7.47-7.51 (1 H, m); 7.52-7.58 (3 H, m); 7.76-7.79 (2 H, m); 7.80-7.85 (1 H, dt, J = 2 & 8 Hz); 8.23 (1 H, s); 8.30 (1 H, d, J = 8 Hz);
5 8.57 (1 H, d); 8.65-8.69 (2 H, m)

UV (λ_{max} in ethanol): 320, 282(sh) & 249 nm

Example 26. The synthesis of 2-(4'-phenyl-2'-pyridyl)-4-(2''-pyridyl)thiazole N',N''-dioxide (26).

10

This compound (26) was synthesized using a method analogous to the synthesis described in Example 19. The yield was 93 %.

¹H NMR (400 MHz, CDCl₃): 7.23-7.27 (1 H, m); 7.41-7.46 (1 H, m); 7.48-7.52 (1 H, m); 7.55-7.60 (3 H, m); 7.74-7.77 (2 H, m);
15 8.41 (1 H, d); 8.45 (1 H, d); 8.69 (1 H, dd); 8.90 (1 H, d); 9.58 (1 H, s)

Example 27. The synthesis of 2-(6'-cyano-4'-phenyl-2'-pyridyl)-4-(6''-cyano-2''-pyridyl)thiazole (27).

20

This compound (27) was synthesized using a method analogous to the synthesis described in Example 20. The yield was 65 %.

¹H NMR (400 MHz, DMSO-d₆): 7.50 (1 H, t, J = 8 Hz); 7.58-7.67 (2 H, m); 7.95 (1 H, d, J = 8 Hz); 8.04-8.08 (2 H, m); 8.24
25 (1 H, t, J = 8 Hz); 8.60 (1H, d, J = 1 Hz); 8.67 (1 H, d, J = 8 Hz); 8.70 (1 H, s); 8.83 (1 H, d, J = 1 Hz)

Example 28. The synthesis of 2-(6'-aminomethyl-4'-phenyl-2'-pyridyl)-4-(6''-aminomethyl-2''-pyridyl)thiazole penta-
30 hydrochloride (28).

This compound (28) was synthesized using a method analogous to the synthesis described in Example 21. The yield was 71 %.

UV (λ_{max} in ethanol): 318 & 251 nm

35

Example 29. The synthesis of 2-{6'-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-4'-phenyl-2'-pyridyl}-4-{6''-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2''-pyridyl}-thiazole (29).

5

This compound (29) was synthesized using a method analogous to the synthesis described in Example 22. The yield was 89 %.

¹H NMR (60 MHz, CDCl₃): 1.47 (36 H, s); 3.54 (4 H, s); 3.58 (4 H, s); 3.95 (2 H, s); 4.18 (2 H, s); 7.42-7.94 (8 H, m); 8.11
10 (1 H, d, J = 2 Hz); 8.20 (1 H, s); 8.43 (1 H, d, J = 2 Hz)

Example 30. The synthesis of 2-{6'-[N,N-bis(carboxymethyl)aminomethyl]-4'-phenyl-2'-pyridyl}-4-{6''-[N,N-bis(carboxymethyl)aminomethyl]-2''-pyridyl}thiazole (30).

15

This compound (30) was synthesized using a method analogous to the synthesis described in Example 9. The yield was 91 %.

20 ¹H NMR (60 MHz, DMSO-d₆): 3.67 (4 H, s); 3.73 (4 H, s); 4.21 (4 H, s); 7.47-7.72 (4 H, m); 7.77-8.25 (5 H, m); 8.40-8.49 (2 H, m)

UV (λ_{max} in water as free ligand): 331(sh) & 252 nm

UV (λ_{max} in water as europium(III) chelate): 334, 288 & 251 nm

25

Example 31. The synthesis of 4-(p-nitrobenzyl)pyridine N-oxide (31).

m-Chloroperbenzoic acid (50-55 %, 74.7 g, about 190 mmol) was
30 added to a cold mixture of 4-(p-nitrobenzyl)pyridine (21.4 g, 100 mmol) and dichloromethane (250 ml). After stirring for two hours, water (200 ml) was added and the reaction mixture was alkalized with solid sodium carbonate. Fractions were separated and the water fraction was extracted with a mixture of
35 ethanol and chloroform (4 :: 150, 1/2). The combined organic

fractions were dried with sodium sulfate. The yield was 19.1 g (83 %).

¹H NMR (60 MHz, CDCl₃): 4.07 (2 H, s); 7.08 (2 H, d, J = 7 Hz); 7.35 (2 H, d, J = 9 Hz); 8.17 (2 H, d, J = 7 Hz); 8.22 (2 H, d, J = 9 Hz)

UV (λ_{max} in ethanol): 273 nm

Example 32. The synthesis of 2-cyano-4-(p-nitrobenzyl)pyridine (32).

10

Trimethylsilylcyanide (50 ml, 400 mmol) was added to a mixture of compound 31 (18.2 g, 79.0 mmol) and dichloromethane (160 ml). After stirring for five minutes, benzoyl chloride (20 ml, 160 mmol) were added and the reaction mixture was stirred for half an hour. Water (160 ml) and solid potassium carbonate (50 g) was added and the reaction mixture was stirred for half an hour. Fractions were separated and the water fraction was extracted with dichloromethane (2 x 100 ml). The organic fractions were dried with sodium sulfate and the product was crystallized from toluene. The yield was 10.0 g (53 %).

20

¹H NMR (60 MHz, CDCl₃): 4.14 (2 H, s); 7.32 (1 H, d, J = 5 Hz); 7.33 (2 H, d, J = 9 Hz); 7.48 (1 H, s); 8.23 (2 H, d, J = 9 Hz); 8.64 (1 H, d, J = 5 Hz)

UV (λ_{max} in ethanol): 266 nm

25

Example 33. The synthesis of 4-(p-nitrobenzyl)pyridine-2-tiocarboxamide (33).

Absolute ethanol saturated with ammonia (20 ml) was added to a cold mixture of compound 32 (4.8 g, 20 mmol), absolute ethanol (100 ml) and dichloromethane (80 ml). The mixture was saturated with hydrogen sulfide. After stirring for overnight, the solution was concentrated. The cold mixture was filtered and washed with cold ethanol. A suspension of the solid material in chloroform (100 ml) was filtered, washed with

35

chloroform and the filtrate was evaporated to dryness. The yield was 3.3 g (60 %).

¹H NMR (60 MHz, CDCl₃): 4.17 (2 H, s); 7.19 (1 H, dd, J = 1 & 5 Hz); 7.35 (2 H, d, J = 8 Hz); 8.19 (2 H, d, J = 8 Hz); 8.44
5 (2 H, d, J = 5 Hz); 8.60 (1 H, d, J = 1 Hz)

mol wt (MS): 273 (M⁺)

UV (λ_{max} in ethanol): 317 & 271 nm

Example 34. The synthesis of 2-[4'-(p-nitrobenzyl)-2'-pyrid-
10 yl]-4-(2''-pyridyl)thiazole (34).

This compound (34) was synthesized using a method analogous to the synthesis described in Example 25. The yield was 61 % after a crystallization from methanol.

15 ¹H NMR (60 MHz, CDCl₃): 4.20 (2 H, s); 7.11-7.50 (4 H, m); 7.69-8.31 (6 H, m); 8.55-8.71 (2 H, m)

UV (λ_{max} in ethanol): 315(sh), 285 & 246 nm

Example 35. The synthesis of 2-[4'-(p-nitrobenzyl)-2'-pyrid-
20 yl]-4-(2''-pyridyl)thiazole N',N''-dioxide (35).

This compound (35) was synthesized using a method analogous to the synthesis described in Example 19. The yield was 82 %.

25 ¹H NMR (60 MHz, DMSO-d₆): 4.32 (2 H, s); 7.33-7.55 (4 H, m); 7.72-7.89 (4 H, m); 8.13-8.69 (4 H, m)

UV (λ_{max} in ethanol): 326 & 253 nm

Example 36. The synthesis of 2-[6'-cyano-4'-(p-nitrobenzyl)-
2'-pyridyl]-4-(6''-cyano-2''-pyridyl)thiazole (36).

30

This compound (36) was synthesized using a method analogous to the synthesis described in Example 20. After the addition of 10 % potassium carbonate, the mixture was extracted several times with chloroform. The combined organic fractions were
35 dried with sodium sulfate. The yield was 69 %.

¹H NMR (60 MHz, CDCl₃): 4.21 (2 H, s); 7.27-7.60 (5 H, m); 7.81-8.20 (4 H, m); 8.33 (1 H, s)

Example 37. The synthesis of 2-[6'-aminomethyl-4'-(p-nitrobenzyl)-2'-pyridyl]-4-(6''-aminomethyl-2''-pyridyl)thiazole pentahydrochloride (37).

This compound (37) was synthesized using a method analogous to the synthesis described in Example 21. After the addition of methanol saturated with hydrogen chloride and stirring for one hour, the solution was evaporated to dryness. The residue was triturated with cold tetrahydrofuran and filtered. The yield was 63 %.

UV (λ_{max} in water): 315(sh), 284 & 242 nm

15

Example 38. The synthesis of 2-{6'-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-4'-(p-nitrobenzyl)-2'-pyridyl}-4-{6''-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2''-pyridyl}thiazole (38).

This compound (38) was synthesized using a method analogous to the synthesis described in Example 22. The product was purified with flash chromatography (silica, petroleum ether/ethyl acetate, 5/2). The yield was 24 %.

¹H NMR (60 MHz, CDCl₃): 1.46 (36 H, s); 3.52 (8 H, s); 3.80 (2 H, s); 3.95 (2 H, s); 4.08 (2 H, s); 7.17-8.17 (10 H, m)

Example 39. The synthesis of 2-{6'-[N,N-bis(carboxymethyl)aminomethyl]-4'-(p-nitrobenzyl)-2'-pyridyl}-4-{6''-[N,N-bis(carboxymethyl)aminomethyl]-2''-pyridyl}thiazole (39).

This compound (39) was synthesized using a method analogous to the synthesis described in Example 9. The yield was 100 %.


¹H NMR (400 MHz, DMSO-d₆): 3.55 (4 H, s); 3.60 (4 H, s); 3.99

(2 H, s); 4.06 (2 H, s); 4.10 (2 H, s); 7.52–7.65 (7 H, m);
8.09–8.22 (3 H, m)


UV (λ_{max} in water as free ligand): 285, 265 & 245 nm

UV (λ_{max} in water as europium(III) chelate): 320(sh) & 285 nm


5



20



35



Scheme 7. The synthesis of compound **42**

Example 40. The synthesis of 2-(4'-(p-aminobenzyl)-6'-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2'-pyridyl)-4-(6'-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2''-pyridyl)-thiazole (**40**).

A mixture of compound **38** (150 mg, 0.17 mmol), 10 % palladium on carbon (10 mg) and methanol (30 ml) was stirred for five hours under hydrogen atmosphere (690 kPa). After filtration and evaporation of the filtrate, the product was purified with flash chromatography (silica, petroleum ether/ethyl acetate, 5/3.). The yield was 40 mg (27 %).

¹H NMR (60 MHz, CDCl₃): 1.45 (36 H, s); 3.51 (8 H, s); 3.77 (2 H, s); 3.92 (2 H, s); 4.06 (2 H, s); 6.64-8.03 (9 H, m); 8.15 (1 H, s)



- 5 Example 41. The synthesis of 2-{4'-(p-aminobenzyl)-6'-[N,N-bis(carboxymethyl)aminomethyl]-2'-pyridyl}-4-{6''-[N,N-bis(carboxymethyl)aminomethyl]-2''-pyridyl}thiazole (**41**).

This compound (**41**) was synthesized using a method analogous
10 to the synthesis described in Example 9. The yield was 100 %.
UV (λ_{\max} in water as free ligand): 315 & 290 nm
UV (λ_{\max} in water as europium(III) chelate): 325 & 290 nm

- 15 Example 42. The synthesis of europium(III) chelate of 2-{4'-[p-(4,6-dichlorotriazon-2-ylamino)benzyl]-6'-[N,N-bis(carboxymethyl)aminomethyl]-2'-pyridyl}-4-{6''-[N,N-bis(carboxymethyl)aminomethyl]-2''-pyridyl}thiazole (**42**).


20 The compound **41** (25 mg, 40 μ mol) was dissolved in water (700 μ l) and the pH was adjusted to 6.5 with solid sodium bicarbonate. Europium (III) chloride (22 mg, 60 μ mol) in water (200 μ l) was added during 15 minutes and the pH was maintained at 5-7. After stirring for 1.5 hours, the pH was raised to 8.5
25 with 1 M sodium hydroxide and the precipitate was filtered off. The filtrate was triturated with acetone, the precipitate was filtered and washed with acetone. A mixture of 2,4,6-trichlorotriazine (2 mg, 10 μ mol), acetone (100 μ l) and water (100 μ l) was added to a solution of the europium(III) chelate
30 (8 mg, 10 μ l) and 0.1 M sodium acetate (150 μ l, pH 4.9). After stirring for 15 minutes, the reaction mixture was triturated with acetone. The precipitate was filtered off, washed with acetone and dried in exsiccator.
UV (λ_{\max} in water): 331, 287 & 250 nm

5



10

15


*m*-ClPBA

20

43 R = H
50 R = NO₂



25

30

(CH₃)₃SiCN, PhCOCl

35

44, 51



41

47, 54

5

 H_2 , Pd/C

Ammonium formate, Pd/C


48

55

10

 CF_3COOH


15

 CF_3COOH 

49

20

25



56

35

Scheme 3. The synthesis of compounds 49 and 56

Example 43. The synthesis of 1-benzyl-3,5-di(2'-pyridyl)-1,2,4-triazole (43).

A mixture of 3,5-di(2'-pyridyl)-1,2,4-triazole (1.12 g, 5.00 mmol), potassium carbonate (1.38 g, 10.0 mmol), benzylchloride (0.63 g, 5.0 mmol) and acetonitrile (65 ml) was refluxed for 2.5 hours. The reaction mixture was filtered and the filtrate was evaporated to dryness. The product was purified with flash chromatography (silica, 1 % methanol in dichloromethane). The yield was 1.05 g (67 %).

^1H NMR (60 MHz, CDCl_3): 6.20 (2 H, s); 6.93-7.38 (6 H, m); 7.58-7.93 (3 H, m); 8.15-8.79 (4 H, m)

Example 44. The synthesis of 1-benzyl-3,5-di(2'-pyridyl)-1,2,4-triazole N',N'-dioxide (44).

This compound (44) was synthesized using a method analogous to the synthesis described in Example 19. The reaction time was 11 days at room temperature. The product was purified with flash chromatography (silica, 2, 5 and 10 % methanol in chloroform). The yield was 62 %.

^1H NMR (60 MHz, CDCl_3): 5.76 (2 H, s); 7.14-7.41 (9 H, m); 7.97-8.45 (4 H, m)

Example 45. The synthesis of 1-benzyl-3,5-bis(6'-cyano-2'-pyridyl)-1,2,4-triazole (45).

This compound (45) was synthesized using a method analogous to the synthesis described in Example 36. The yield was 71 %.

^1H NMR (400 MHz, CDCl_3): 6.15 (2 H, s); 7.26 (1 H, t, $J = 7$ Hz); 7.32 (2 H, t, $J = 7$ Hz); 7.42 (2 H, d, $J = 7$ Hz); 7.75-7.78 (2 H, m); 7.79 (1 H, t, $J = 8$ Hz); 8.01 (1 H, t, $J = 8$ Hz); 8.47 (1 H, dd, $J = 1$ & 8 Hz); 8.64 (1 H, dd, $J = 1$ & 8 Hz)

Example 46. The synthesis of 3,5-bis(6'-aminomethyl-2'-pyridyl)-1-benzyl-1,2,4-triazole pentahydrochloride (**46**).

This compound (**46**) was synthesized using a method analogous to the synthesis described in Example 37. The yield was 100 %.

¹H NMR (400 MHz, CDCl₃): 4.26 (2 H, s); 4.28 (2 H, s); 5.87 (2 H, s); 7.03-7.50 (m, 7 H); 7.88-8.03 (4 H, m)

10 Example 47. The synthesis of 1-benzyl-3,5-bis{6'-bis[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2'-pyridyl}-1,2,4-triazole (**47**).

This compound (**47**) was synthesized using a method analogous to the synthesis described in Example 22. The product was purified with flash chromatography (silica, petroleum ether/ethyl acetate, 1/1). The yield was 39 %.

¹H NMR (60 MHz, CDCl₃): 1.45 (36 H, s); 3.47 (4 H, s); 3.52 (4 H, s); 4.08 (2 H, s); 4.21 (2 H, s); 6.20 (2 H, s); 7.13-7.30 (5 H, m); 7.54-7.83 (4 H, m); 7.95-8.33 (2 H, m)

Example 48. The synthesis of 3,5-bis{6'-bis[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2'-pyridyl}-1,2,4-triazole (**48**).

25

A mixture of compound **47** (0.44 g, 0.53 mmol), 10 % palladium on carbon (0.25 g), ammonium formate (about 1.0 g, 15 mmol), methanol (10 ml) under nitrogen atmosphere was stirred several days at room temperature. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was dissolved in chloroform (50 ml), washed with water (20 ml) and dried with sodium sulfate. The yield was 0.34 g (87 %).

¹H NMR (60 MHz, CDCl₃): 1.46 (36 H, s); 3.35 (4 H, s); 3.52 (4 H, s); 4.12 (2 H, s); 4.17 (2 H, s); 7.57-8.25 (6 H, m)

35

Example 49. The synthesis of 3,5-bis(6'-bis[N,N-bis(carboxymethyl)aminomethyl]-2'-pyridyl)-1,2,4-triazole (49).

This compound (49) was synthesized using a method analogous to the synthesis described in Example 9. The yield was 100 %.
UV (λ_{\max} in water as free ligand): 284 & 232 nm
UV (λ_{\max} in water as europium chelate): 288 & 233 nm

Example 50. The synthesis of 1-(*m*-nitrobenzyl)-3,5-di(2'-pyridyl)-1,2,4-triazole (50).

This compound (50) was synthesized using a method analogous to the synthesis described in Example 43. The yield was 78 %.
 ^1H NMR (60 MHz, CDCl_3): 6.27 (2 H, s); 7.20-7.86 (6 H, m);
7.91-8.52 (4 H, m); 8.62-8.80 (2 H, m)

Example 51. The synthesis of 1-(*m*-nitrobenzyl)-3,5-di(2'-pyridyl)-1,2,4-triazole N',N' -dioxide (51).

This compound (51) was synthesized using a method analogous to the synthesis described in Example 44. The product was purified with flash chromatography (silica, 3, 7 and 10 % methanol in chloroform). The yield was 51 %.
 ^1H NMR (60 MHz, CDCl_3): 5.80 (2 H, s); 7.05-8.05 (10 H, m);
8.32-8.53 (1 H, m); 9.29 (1 H, m)
mol wt (MS): 390 (M^+)

Example 52. The synthesis of 3,5-bis(6'-cyano-2'-pyridyl)-1-(*m*-nitrobenzyl)-1,2,4-triazole (52).

30

This compound (52) was synthesized using a method analogous to the synthesis described in Example 36. The product was purified with flash chromatography (silica, ethyl acetate). The yield was 55 %.

^1H NMR (60 MHz, CDCl_3): 6.24 (2 H, s); 7.52-8.24 (8 H, m);

8.48 (1 H, dd); 8.70 (1 H, dd)

UV (λ_{max} in ethanol): 287(sh) & 254 nm

mol wt (MS): 408 (M⁺)

5 Example 53. The synthesis of 3,5-bis(6'-aminomethyl-2'-pyridyl)-1-(*m*-nitrobenzyl)-1,2,4-triazole pentahydrochloride (**53**).

This compound (**53**) was synthesized using a method analogous to the synthesis described in Example 37. The yield was 82 %.

10 ¹H NMR (60 MHz, CDCl₃): 4.25 (4 H, s); 5.97 (2 H, s); 7.20-8.05 (10 H, m)

Example 54. The synthesis of 3,5-bis(6'-bis[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2'-pyridyl)-1-(*m*-nitro-
15 benzyl)-1,2,4-triazole (**54**).

This compound (**54**) was synthesized using a method analogous to the synthesis described in Example 22. The product was purified with flash chromatography (silica, petroleum ether/
20 ethyl acetate, 1/1). The yield was 42 %.

¹H NMR (60 MHz, CDCl₃): 1.44 (18 H, s); 1.45 (18 H, s); 3.47 (4 H, s); 3.52 (4 H, s); 4.10 (2 H, s); 4.22 (2 H, s); 6.32 (2 H, s); 7.30-8.39 (10, m)

UV (λ_{max} in ethanol): 283 & 237 nm

25

Example 55. The synthesis of 1-(*m*-aminobenzyl)-3,5-bis(6'-bis[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2'-pyridyl)-1,2,4-triazole (**55**).

30 This compound (**55**) was synthesized using a method analogous to the synthesis described in Example 40. The product was purified with flash chromatography (silica, 5 % methanol in chloroform). The yield was 85 %.

¹H NMR (60 MHz, CDCl₃): 1.45 (36 H, s); 3.48 (4 H, s); 3.52 (4
35 H, s); 4.10 (2 H, s); 4.22 (2 H, s); 6.10 (2 H, s); 6.41-7.01

(4 H, m); 7.70–8.33 (6 H, m)


Example 56. The synthesis of 1-(*m*-aminobenzyl)-3,5-bis(6'-bis[N,N-bis(carboxymethyl)aminomethyl]-2'-pyridyl)-1,2,4-5 triazole (56).

This compound (56) was synthesized using a method analogous to the synthesis described in Example 9. The yield was 100 %.

¹H NMR (400 MHz, DMSO-d₆): 3.54 (4 H, s); 3.62 (4 H, s); 4.09 (2 H, s); 4.14 (2 H, s); 6.10 (2 H, s); 6.80–6.88 (2 H, m); 6.96–7.02 (1 H, m); 7.19–7.23 (1 H, m); 7.69 (1 H, d); 7.73 (1 H, d); 7.97 (1 H, t); 8.04 (1 H, t); 8.05 (1 H, d); 8.17 (1 H, d)

UV (λ_{max} in water as free ligand): 282 & 234 nm

UV (λ_{max} in water as europium(III) chelate): 293, 282 & 236 nm



35

Scheme 3. The synthesis of compounds 57a and 57b

Example 57a. The synthesis of europium(III) chelate of 1-[m-(4,6-dichlorotriazon-2-ylamino)benzyl]-3,5-bis{6'-bis[N,N-bis-(carboxymethyl)aminomethyl]-2'-pyridyl}-1,2,4-triazole (**57a**).


5 This compound (**57a**) was synthesized using a method analogous to the synthesis described in Example 42.

UV (λ_{\max} in water): 295(sh), 282 & 236 nm.


10 Example 57b. The synthesis of terbium(III) chelate of 1-[m-(4,6-dichlorotriazon-2-ylamino)benzyl]-3,5-bis{6'-bis[N,N-bis-(carboxymethyl)aminomethyl]-2'-pyridyl}-1,2,4-triazole (**58**).

This compound (**57b**) was synthesized using a method analogous to the synthesis described in Example 42.


UV (λ_{\max} in water): 295(sh), 282 & 237 nm.





25




48



one isomer shown



35




10

 $\text{BrCH}_2\text{COO-tert-Bu}$ $\text{H}_2, \text{Pd/C}$

64

15



30

Ammonium formate

 CF_3COOH


66

67

Pd/C

35

50



Scheme 10. The synthesis of compound 68

15

Example 58. The synthesis of 2-pyridylhydrazide (58).

Hydrazine hydrate (17.5 ml, 500 mmol) in ethanol (50 ml) was added to a solution of ethyl 2-pyridinecarboxylate (7.53 g, 50.0 mmol) and ethanol (25 ml). After evaporation and coevaporation with toluene, the product was crystallized from toluene. The yield was 6.1 g (86 %).

^1H NMR (60 MHz, $\text{DMSO}-d_6$): 4.49 (3 H, bs); 7.44–7.74 (1 H, m); 7.94–8.04 (2 H, m); 8.56–8.68 (1 H, m)

UV (λ_{max} in ethanol): 265 & 216 nm

Example 59. The synthesis of 3-[4'-(p-nitrobenzyl)-2'-pyridyl]-5-(2''-pyridyl)-1,2,4-triazole (59).

30

A mixture of compounds 32 (4.80 g, 20.0 mmol) and 58 (2.74 g, 20.0 mmol) was stirred for 24 hours at 160°C. The reaction mixture was treated several times with hot toluene and the combined toluene fractions were evaporated to dryness. The residue was dissolved in 10 % methanol in chloroform, filtered

35

through a short silica column and the filtrate was evaporated to dryness. The yield was 5.6 g (78 %).

¹H NMR (400 MHz, CDCl₃): 4.17 (2 H, s); 7.20 (1 H, d, J = 4.7 Hz); 7.33-7.39 (1 H, m); 7.39 (2 H, d, J = 8.4 Hz); 7.85-7.90 (1 H, m); 8.18 (2 H, d, J = 8.4 Hz); 8.25 (1 H, s); 8.35 (1 H, d, J = 8.1 Hz); 8.72 (1 H, d, J = 5.0 Hz); 8.78 (1 H, d, J = 4.7 Hz)

UV (λ_{\max} in ethanol): 275 nm

10 Example 60. The synthesis of 1(and 2)-benzyl-3-[4'-(p-nitro-benzyl)-2'-pyridyl]-5-(2''-pyridyl)-1,2,4-triazole (**60**).

This compound (**60**) was synthesized using a method analogous to the synthesis described in Example 43. The yield was 76 %.

15 ¹H NMR (60 MHz, CDCl₃): 4.12 (2 H, s); 6.19 (2 H, s); 6.86-8.73 (16 H, m)

UV (λ_{\max} in ethanol): 279 nm

20 Example 61. The synthesis of 1(and 2)-benzyl-3-[4'-(p-nitro-benzyl)-2'-pyridyl]-5-(2''-pyridyl)-1,2,4-triazole N',N''-dioxide (**61**).

This compound (**61**) was synthesized using a method analogous to the synthesis described in Example 44. The product was purified with flash chromatography (silica, 2, 5 and 10 % methanol in chloroform). The yield was 50 %.

25 ¹H NMR (400 MHz, CDCl₃, aliphatic area, isomer 1): 3.96 (2 H, s); 5.79 (2 H, s)

30 ¹H NMR (400 MHz, CDCl₃, aliphatic area, isomer 2): 4.10 (2 H, s); 5.75 (2 H, s)

Example 62. The synthesis of 1(and 2)-benzyl-3-[6'-cyano-4'-(p-nitrobenzyl)-2'-pyridyl]-5-(6''-cyano-2''-pyridyl)-1,2,4-triazole (62).

5 This compound (62) was synthesized using a method analogous to the synthesis described in Example 36. The product was purified with flash chromatography (silica, 5/3, 1/1 and 0/1 petroleum ether/ethyl acetate). The yield was 51 %.

¹H NMR (400 MHz, CDCl₃, isomer 1): 4.24 (2 H, s); 6.13 (2 H, s); 7.27 (1 H, t, J = 7 Hz); 7.31 (2 H, t, J = 7 Hz); 7.39 (2 H, d, J = 7 Hz); 7.41 (2 H, d, J = 9 Hz); 7.54 (1 H, s); 7.76 (1 H, d, J = 8 Hz); 8.00 (1 H, d, J = 8 Hz); 8.24 (2 H, d, J = 9 Hz); 8.29 (1 H, s); 8.60 (1 H, d, J = 8 Hz)

¹H NMR (400 MHz, CDCl₃, isomer 2): 4.20 (2 H, s); 6.13 (2 H, s); 7.26 (1 H, t, J = 7 Hz); 7.31 (2 H, t, J = 7 Hz); 7.37 (2 H, d, J = 9 Hz); 7.40 (2 H, d, J = 7 Hz); 7.50 (1 H, s); 7.77 (1 H, d, J = 8 Hz); 7.99 (1 H, t, J = 8 Hz); 8.22 (2 H, d, J = 9 Hz); 8.45 (1 H, d, J = 8 Hz); 8.54 (1 H, s)

UV (λ_{max} in ethanol): 263 nm

20

Example 63. The synthesis of 3-[6'-aminomethyl-4'-(p-nitrobenzyl)-2'-pyridyl]-5-(6''-aminomethyl-2''-pyridyl)-1(and 2)-benzyl-1,2,4-triazole pentahydrochloride (63).

25 This compound (63) was synthesized using a method analogous to the synthesis described in Example 37. The yield was 88 %.

UV (λ_{max} in water): 280 & 235(sh)

Example 64. The synthesis of 1(and 2)-benzyl-3-(6'-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-4'-(p-nitrobenzyl)-2'-pyridyl)-5-(6''-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2''-pyridyl)-1,2,4-triazole (64).

This compound (64) was synthesized using a method analogous to the synthesis described in Example 21. The product was

35

purified with flash chromatography (silica, petroleum ether/ethyl acetate, 1/1). The yield was 44 %.

¹H NMR (400 MHz, CDCl₃, isomer 1, aliphatic area): 1.45 (36 H, s); 3.46 (4 H, s); 3.48 (4 H, s); 4.06 (2 H, s); 4.15 (2 H, s); 4.19 (2 H, s); 6.19 (2 H, s)

¹H NMR (400 MHz, CDCl₃, isomer 2, aliphatic area): 1.45 (36 H, s); 3.44 (4 H, s); 3.51 (4 H, s); 4.05 (2 H, s); 4.12 (2 H, s); 4.20 (2 H, s); 6.19 (2 H, s)

UV (λ_{max} in ethanol): 283 & 250 nm

10

Example 65. The synthesis of 1(and 2)-benzyl-3-(6'-[N,N-bis-(tert-butoxycarbonylmethyl)aminomethyl]-4'-(p-aminobenzyl)-2'-pyridyl)-5-(6''-[N,N-bis-(tert-butoxycarbonylmethyl)aminomethyl]-2''-pyridyl)-1,2,4-triazole (65).

15

This compound (65) was synthesized using a method analogous to the synthesis described in Example 40. The product was purified with flash chromatography (silica, 2 and 3 % methanol in chloroform). The yield was 36 %.

20 ¹H NMR (400 MHz, CDCl₃, isomer 1): 1.45 (36 H, s); 3.46 (4 H, s); 3.50 (4 H, s); 3.93 (2 H, s); 4.05 (2 H, s); 4.19 (2 H, s); 6.19 (2 H, s); 6.62 (2 H, d, J = 8 Hz); 7.01 (2 H, d, J = 8 Hz); 7.15-7.35 (5 H, m); 7.65 (1 H, s); 7.71 (1 H, d, J = 8 Hz); 7.79 (1 H, t, J = 8 Hz); 7.91 (1 H, s); 8.23 (1 H, d, J = 8 Hz)

25

¹H NMR (400 MHz, CDCl₃, isomer 2): 1.45 (36 H, s); 3.45 (4 H, s); 3.51 (2 H, s); 3.90 (2 H, s); 4.03 (2 H, s); 4.21 (2 H, s); 6.19 (2 H, s); 6.61 (2 H, d, J = 8 Hz); 6.98 (2 H, d, J = 8 Hz); 7.15-7.35 (5 H, m); 7.50 (1 H, s); 7.78 (1 H, t, J = 8 Hz); 7.83 (1 H, d, J = 8 Hz); 8.07 (1 H, d, J = 8 Hz); 8.12 (1 H, s)

30

35

Example 66. The synthesis of 3-{6'-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-4'-(p-aminobenzyl)-2'-pyridyl}-5-{6''-[N,N-bis(tert-butoxycarbonylmethyl)aminomethyl]-2''-pyridyl}-1,2,4-triazole (66).

5

This compound (66) was synthesized using a method analogous to the synthesis described in Example 48. The yield was 50 %. ¹H NMR (60 MHz, CDCl₃, aliphatic area): 1.45 (36 H, s); 3.50 (8 H, s); 3.91 (2 H, s); 4.09 (2 H, s); 4.16 (2 H, s)

10

Example 67. The synthesis of 3-{6'-[N,N-bis(carboxymethyl)aminomethyl]-4'-(p-aminobenzyl)-2'-pyridyl}-5-{6''-[N,N-bis(carboxymethyl)aminomethyl]-2''-pyridyl}-1,2,4-triazole (67).

15


This compound (67) was synthesized using a method analogous to the synthesis described in Example 9. The yield was 100 %.

20 Example 68. The synthesis of terbium(III) chelate of 3-{6'-[N,N-bis(carboxymethyl)aminomethyl]-4'-(p-isothiocyanatobenzyl)-2'-pyridyl}-5-{6''-[N,N-bis(carboxymethyl)aminomethyl]-2''-pyridyl}-1,2,4-triazole (68).

25 The compound 68 (50 mg, 0.08 mmol) was dissolved in water (1.5 ml) and the pH was adjusted to 6.5 with solid sodium bicarbonate. Terbium(III) chloride (35 mg, 0.090 mmol) in water (0.5 ml) was added during 15 minutes and the pH was maintained at 5-7. After stirring for 1.5 hours, the pH was raised to 8.5
30 with 1 M sodium hydroxide and the precipitate was filtered off. The filtrate was triturated with acetone, the precipitate was filtered and washed with acetone. An aqueous solution of the precipitate (2.5 ml) was added during 15 minutes to a mixture of thiophosgene (25 ul, 0.32 mmol), sodium bicarbonate
35 (34 mg, 0.40 mmol) and chloroform (2.5 ml). After stirring for

one hour, the fractions were separated and the water fraction was washed with chloroform (3 x 1.0 ml). The aqueous solution was triturated with acetone, the precipitate was filtered and washed with acetone. The yield was 38 mg (55 %).

5



35 Scheme 11. The synthesis of compound 72

Example 69. The synthesis of 2,4-di(2'-pyridyl)imidazole (69).

A mixture of 2-pyridinecarboxamidine hydrochloride (4.85 g, 31.0 mmol), 2-bromoacetylpyridine (5.00 g, 25.0 mmol), N,N-diisopropylethylamine (8.8 ml, 50 mmol) and chloroform (50 ml) was refluxed for two hours. The reaction mixture was washed with 5 % sodium bicarbonate (20 ml), water (2 x 20 ml) and dried with sodium sulfate. The product was purified with flash chromatography (silica, ammonia/5 % methanol in chloroform, first 0/1 then 1/49). The yield was 2.28 g (41 %). M.p. 145°C.
¹H NMR (400 MHz, CDCl₃): 7.15-7.18 (1 H, m); 7.27-7.30 (1 H, m); 7.72 (2 H, t); 7.80 (2 H, t); 8.22 (1 H, d); 8.58-8.59 (2 H, d)
UV (λ_{max} in ethanol): 307, 260 & 227 nm

Example 70. The synthesis of 1-acetoxymethyl-2,4-di(2'-pyridyl)imidazole (70).

A mixture of compound 69 (0.50 g, 2.3 mmol), potassium carbonate (0.48, 3.4 mmol), bromomethyl acetate (1.03 g, 6.80 mmol) in acetonitrile (20 ml) was refluxed for five hours. After filtration the filtrate was evaporated to dryness. The product was purified with flash chromatography (silica, 2 and 5 % methanol in chloroform). The yield was 0.40 g (59 %).
¹H NMR (400 MHz, CDCl₃): 2.07 (3 H, s); 6.69 (2 H, s); 7.16-7.19 (1 H, m); 7.27-7.30 (1 H, m); 7.75 (1 H, dt, J = 1 & 8 Hz); 7.81 (1 H, dt, J = 1 & 8 Hz); 7.92 (1 H, s); 8.07 (1 H, d, J = 8 Hz); 8.35 (1 H, d, J = 8 Hz); 8.59-8.61 (2 H, m)
UV (λ_{max} in ethanol): 294, 257 & 223 nm

Example 71. The synthesis of 1-acetoxymethyl-2,4-di(2'-pyridyl)imidazole N',N'-dioxide (71).

This compound (71) was synthesized using a method analogous to the synthesis described in Example 44. The product was

purified with flash chromatography (silica, 2, 5 and 10 % methanol in chloroform). The yield was 20 %.

^1H NMR (400 MHz, CDCl_3): 1.98 (3 H, s); 6.14 (2 H, s); 7.15 (1 H, dt); 7.32 (1 H, t); 7.40-7.43 (2 H, m); 7.72-7.75 (1 H, m);
5 8.31-8.35 (3 H, m); 8.92 (1 H, s)

UV (λ_{max} in ethanol): 289(sh), 254 & 220 nm

Example 72. The synthesis of 1-acetoxymethyl-2,4-bis(6'-cyano-2'-pyridyl)imidazole (72).


10

This compound (72) was synthesized using a method analogous to the synthesis described in Example 36. The product was purified with flash chromatography (silica, petroleum ether/ethyl acetate, 5/3). The yield was 52 %.


15 ^1H NMR (400 MHz, CDCl_3): 2.11 (3 H, s); 6.61 (2 H, s); 7.57 (1 H, d, $J = 8$ Hz); 7.71 (1 H, d, $J = 8$ Hz); 7.86 (1 H, t, $J = 8$ Hz); 7.97 (1 H, t, $J = 8$ Hz); 8.04 (1 H, s); 8.25 (1 H, d, $J = 8$ Hz); 8.57 (1 H, d, $J = 8$ Hz)

UV (λ_{max} in ethanol): 301 & 272 nm


20



25




30



35

74



Scheme 12. The synthesis of compound 76

Example 73. The synthesis of 2,6-bis(4'-methylthiazol-2'-yl)-pyridine (73).

A mixture of 2,6-pyridinedithiodicarboxamide (0.74 g, 3.8 mmol), chloroacetone (0.70 ml, 8.7 mmol) and ethanol (15 ml) was refluxed overnight. Solid material was filtered and washed with ethanol. The suspension of the hydrochloric salt of the product in hot water (50 ml) was alkalized with solid sodium carbonate. The product was filtered and washed with water. The yield was 0.63 g (61 %).

^1H NMR (400 MHz, CDCl_3): 2.54 (6 H, s); 7.03 (2 H, s); 7.86 (1 H, t, $J = 7.8$ Hz); 8.15 (2 H, d, $J = 7.8$ Hz)

UV (λ_{max} in ethanol): 330, 306 & 232 nm

Example 74. The synthesis of 2,6-bis(4'-bromomethylthiazol-2'-yl)pyridine (74).

A mixture of compound 73 (0.63 g, 2.3 mmol), N-bromosuccinimide (0.90 g, 5.1 mmol), dibenzoylperoxide (56 mg, 0.2 mmol) and carbon tetrachloride (15 ml) was refluxed overnight. The reaction mixture was filtered and the filtrate was

evaporated to dryness. The product was purified with flash chromatography (silica, 2 % methanol in chloroform). The yield was 82 %.

¹H NMR (400 MHz, CDCl₃): 4.65 (4 H, s); 7.44 (2 H, s); 7.93 (1
5 H, t, J = 9 Hz); 8.24 (2 H, d, J = 9 Hz)

UV (λ_{max} in ethanol): 328 & 302 nm

Example 75. The synthesis of 2,6-bis(4'-[N,N-bis(tert-butoxy-
10 carbonylmethyl)aminomethyl]thiazol-2'-yl)pyridine (75).

This compound (75) was synthesized using a method analogous to the synthesis described in Example 8. The product was purified with flash chromatography (silica, petroleum ether/
15 ethyl acetate, first 10/1, then 5/1). The yield was 31 %.

¹H NMR (400 MHz, CDCl₃): 1.48 (36 H, s); 3.53 (8 H, s); 4.16 (4 H, s); 7.42 (2 H, s); 7.86 (1 H, t, J = 8.0 Hz); 8.18 (2 H, d, J = 8.0 Hz)

UV (λ_{max} in ethanol): 329 & 299 nm

20

Example 76. The synthesis of 2,6-bis(4'-[N,N-bis(carboxymethyl)aminomethyl]thiazol-2'-yl)pyridine (76).


25 This compound (76) was synthesized using a method analogous to the synthesis described in Example 9. The yield was 75 %.

¹H NMR (400 MHz, DMSO-d₆): 3.85 (8 H, s); 4.33 (4 H, s); 7.90 (2 H, s); 8.18-8.22 (3 H, m)

UV (λ_{max} in water as free ligand): 323 & 287 nm

30 UV (λ_{max} in water as europium(III) chelate): 341 & 278 nm

35



20 **Example 77.** The synthesis of 2,6-bis(N-hydroxycarboximidamido)pyridine (**77**).

A mixture of 2,6-dicyanopyridine (8.03 g, 62.2 mmol), hydroxylamine hydrochloride (10.4 g, 150 mmol), sodium acetate (13.8 g, 168 mmol) and water/ethanol (200 ml, 1/5) was refluxed for 45 minutes. After evaporation to dryness the residue was trituated with water, filtered and washed with water. The yield was 11.43 g (94 %).

¹H NMR (60 MHz, DMSO-d₆): 6.26 (4 H, bs); 7.70–7.87 (3 H, m); 9.83 (2 H, s)



UV (λ_{max} in ethanol): 301 nm

Example 78. The synthesis of 2,6-bis(5'-methyl-1',2',4'-oxadiazol-3'-yl)pyridine (**78**).

A mixture of compound **77** (11.1 g, 57.0 mmol), acetic anhydride (34.9 g, 342 mmol) and toluene (150 ml) was refluxed overnight. After evaporation to the half of the original volume, the solid material was filtered and washed with toluene. The yield was 11.6 g (84 %).

¹H NMR (400 MHz, CDCl₃): 2.71 (6 H, s); 8.03 (1 H, t, J = 7.7 Hz); 8.21 (2 H, d, J = 7.7 Hz)

UV (λ_{max} in ethanol): 282 & 233 nm



30 Scheme 14. The synthesis of compound **79**

Example 79. The synthesis of europium(III) cryptate (**79**).

A mixture of europium(III) acetate (78 mg, 0.24 mmol), trimethyl orthoformate (1.2 ml) and dry acetonitrile (6 ml) was

35

refluxed for two hours. After addition of 1,7,10,16-tetraoxa-4,13-diazacyclooctadecane (62 mg, 0.24 mmol) the reaction mixture was refluxed for 15 minutes. A suspension of compound 12 (130 mg, 0.24 mmol) and dry acetonitrile (4 ml) was added and the reaction mixture was refluxed for 24 hours. The product was filtered and washed with acetonitrile. The yield was 70 mg (37 %).

Example 80. The synthesis of terbium(III) chelate of 3-{6'-[N,N-bis(carboxymethyl)aminomethyl]-4'-[p-(4,6-dichlorotriaz-2-ylamino)benzyl]-2'-pyridyl]-5-{6''-[N,N-bis(carboxymethyl)aminomethyl]-2''-pyridyl]-1,2,4-triazole (80).

This compound (80) was synthesized from the compound 67 using a method analogous to the synthesis described in Example 57b.

Example 81. The luminescence properties of europium(III) and terbium(III) chelates of the compound 49.

The relative luminescence yield ϕ_{rel} of the europium(III) and terbium(III) chelates of the compound 49 were measured in equimolar 10^{-5} M solutions of the compound 49 and the corresponding lanthanide ion. Luminescence measurements were done on a Perkin-Elmer LS-5^o spectrofluorometer using the phosphorescence mode which allowed the decay curves of the lanthanide luminescence to be measured. The luminescence yield is reported relative to the luminescence of the uncomplexed lanthanide cation (Ln) using the equation:

$$\phi_{rel} = \frac{I_{che} C_{Ln} k_{Ln}}{I_{Ln} C_{che} k_{che}}$$

where I_{che} and I_{Ln} are the preexponential terms of the emission decay curves for the chelated and uncomplexed lanthanide cation, respectively (614 nm for europium and 544 nm for terbium). The excitation wavelength for the uncomplexed europium(III) was 395 nm and for terbium(III) 370 nm. C_{Ln} and C_{che} are the concentrations of free and complexed lanthanide

cation, respectively, and k_{Ln} and k_{che} the corresponding decay constants. For the europium(III) complex of the compound **49** the relative luminescence yield was 1.3×10^5 and for the terbium(III) complex it was 5.8×10^5 . The excitation wavelength for europium(III) was 280 nm and for terbium(III) 310 nm.

Example 82. The luminescence properties of europium(III) and terbium(III) chelates of the compound **30**.

For the europium(III) complex of the compound **30** the relative luminescence yield was 8.9×10^5 . The excitation wavelength was 336 nm. For terbium(III) the corresponding values were 2.8×10^3 and 260 nm.

Example 83. The luminescence properties of the europium(III) chelate of the compound **76**.

For the europium(III) complex of the compound **76** the relative luminescence yield was 5.7×10^5 . The excitation wavelength was 340 nm.

Example 84. The labelling of Rabbit-anti-mouse IgG with the compound **68**.

IgG fraction of rabbit-anti-mouse-IgG (RaM) (Dako, Denmark) was purified into a labelling buffer consisting of 50 mM carbonate (pH 9.3). RaM fractions (1 mg each) were labelled with the chelate **68** using a 100, 300 and 1200 fold molar excess of the chelate in the labelling buffer, incubating at room temperature for 16 hours. Thereafter the IgG-conjugates were purified with a combined column of Trisacryl® GF5 (Reactifs IBF, France) and Sephacryl® S-300 (Pharmacia Biosystems, Sweden), eluting with tris-buffered salt solution (50 mM, pH 7.75). Both the partly aggregated and monomeric IgG fractions were collected and analyzed for protein and terbium(III) concentration. Terbium(III) concentrations were measured with a modified DELFIA® system (Wallac, Finland) using 2,4,6-trimethoxyphenyldipicolinic acid as the fluoregenic ligand. The incorporation yields varied between 12.2 and

69 terbium(III)/IgG.

Example 85. The relative luminescence of terbium(III)-labelled antibodies.

5

The relative luminescence of labelled antibodies were measured in different buffers in the pH range between 3.2 and 11.7. The highest luminescences were achieved at neutral pH, at pH below 5 luminescence decreased rapidly, at pH over 9 the decrease was slow. The luminescence was not quenched by innerfilter effect. The excitation maximum was at 310 nm, producing the typical emission lines at 490 and 544 nm (in addition to minor lines at longer wavelenght). The quantum yield compared to the system in Example 83 approached 25 % and the decay time was 1.46 ms (in buffer).

10

15

Example 86. The immunoassay with terbium(III)-labelled antibodies.

20 The immunoreactivity of the present terbium(III)-labelled antibodies were tested in a model assay system consisting of polystyrene microtitration strips physically coated with monoclonal antibodies (MIgG) using albumin (BSA) coated strips as a control. The strips were incubated in assay buffer (Wallac) containing varying amounts of terbium(III)-labelled RaM. The specific signal ranged from 3000 cps with 1 ng/ml of the terbium(III)-RaM to 1,000,000 cps with 10 µg/ml of terbium(III)-RaM.

25


30 Terbium(III)-labelled RaM was also tested in an allergy-specific IgE binding test using a matrix (CAP® matrix, Pharmacia Diagnostics) immobilized with allergenic material. The binding of specific IgE from patient serum was visualized by staining with mouse-anti-human IgE and subsequently with terbium(III)-labelled RaM. The stained matrix was examined with a time-resolved fluorescence microscope and the signal recorded with a CCD camera.

35

Claims


1. A luminescent lanthanide chelate consisting of a lanthanide ion and a chelator of the formula

5




characterized in that



- 10 a) - represents a covalent bond between two carbon atoms;
 b) - represents a covalent bond;
 c) E represents methylene (CH₂) or carbonyl (C=O);
 d) one or two of [A₁], [B] and [A₂] is/are bivalent
 15 heterocyclic unsaturated five-membered rings selected from





20













25



30



- 2-oxazolin-2,4-ylene: 
- 5 3-oxazolin-2,4-ylene: 
- 2,4-imidazolylene: 
- 10 2-imidazolin-2,4-ylene: 
- 3-imidazolin-2,4-ylene: 
- 15 1,2,4-triazol-3,5-ylene: 
- 20 1,3,4-oxadiazol-2,5-ylene: 
- 1,2,4-oxadiazol-3,5-ylene: 
- 25 1,3-pyrazolylene:  or
- 2,5-pyrrolylene: 

30 and corresponding rings in which one hydrogen is replaced with the appropriate group G_1 , G_2 and G_3 , same or different,

the remaining group(s) $[A_1]$, $[B]$ and $[A_2]$ is/are

2,6-pyridylene or the corresponding ring in which one hydrogen is replaced with the appropriate group G_1 , G_2 and G_3 , same or different,

5 one heteroatom in each ring $[A_1]$, $[B]$ and $[A_2]$ is coordinating to the same lanthanide ion so that two five-membered rings are formed in which one member is the lanthanide ion and two members are coordinating heteroatoms of different rings $[A_1]$, $[B]$ and $[A_2]$, and

10 e) Ch_1 and Ch_2 represent identical or different chelating groups, possibly linked together,

each of which comprising at least two heteroatoms that are coordinated to the lanthanide ion and are selected from the group consisting of oxygen and
15 nitrogen, and at least one of the said coordinating heteroatoms in each of Ch_1 and Ch_2 is forming a five- or six-membered ring together with the lanthanide ion and a coordinating heteroatom of one of $[A_1]$, $[B]$ and $[A_2]$,

20 the distance between each pair of heteroatoms participating in the chelation and forming the same five- or six-membered ring being two or three atoms, respectively,

f) G_1 , G_2 and G_3 , respectively, are selected from the
25 group consisting of hydroxy, nitro, amino or lower alkyl substituted amino, lower aryl substituted amino or lower acyl substituted amino, alkyl, aryl, alkyl-aryl, arylalkyl, arylolefinyl, such as phenylethynyl, alkoxy or aryloxy groups, with the proviso alkyls contain 1-12 carbon atoms and aryls are selected from
30 phenyl, naphthyl and pyridyl,

or a group containing aryl and alkylene parts in which the alkylene part contains from 1 to 8 carbon atoms and additionally 0 to 4 other atoms such as

oxygen, sulphur, nitrogen or phosphorus and aryl is selected from phenyl, naphthyl and pyridyl, and

5 each of the above mentioned groups optionally contain amino, aminooxy, carboxyl, hydroxy, aldehyde or mercapto groups or an activated form made from them such as isothiocyanato, isocyanato, diazonium, bromoacetamido, iodoacetamido, reactive esters, such as N-hydroxysuccinimido, 4-nitrophenyl and 2,4-dinitrophenyl, pyridyl-2-dithio, 4-chloro-6-ethoxy-
10 triazon-2-ylamino or 4,6-dichlorotriazon-2-ylamino for the binding to a compound exhibiting biospecific affinity.

2. The chelate of claim 1, characterized in that [B] is
15 2,6-pyridylene or the corresponding group in which one hydrogen is replaced with G₂.

3. The chelate of claim 1, characterized in that [A₁] and [A₂] are 2,6-pyridylene or the corresponding group in which
20 one hydrogen is replaced with G₁ and G₃, respectively.

4. The chelate of any of claims 1-3 characterized in that the lanthanide ion is selected from Eu³⁺, Tb³⁺, Sm³⁺ and Dy³⁺.

25 5. The chelate of any of claims 1-4, characterized in that the chelating heteroatoms of Ch₁ and Ch₂ are selected from amino nitrogens (primary, secondary or tertiary) and negatively charged oxygens such as in carboxylates, phosphonates and phosphates.

30 6. The chelate of any of claims 1-5 characterized in that Ch₁ and Ch₂ are selected from the group consisting of N(CH₂COO⁻)₂, N(CH₂CH₂COO⁻)₂, N(CH₂-PO₃²⁻)₂ or a 2,6-dicarboxypiperidin-1-yl.

7. The chelate of any of claims 1-5, characterized in that
Ch₁ and Ch₂ form one or two bridges consisting of saturated
carbon, ether oxygen and nitrogen atoms, said bridges
5 covalently connecting [A₁] and [A₂] and said nitrogen being
selected from secondary or tertiary amino nitrogens.

8. The chelate of any of claims 1-7 additionally comprising
a residue of a compound exhibiting biospecific affinity
10 selected from the group consisting of proteins, enzymes,
antibodies, antigens, haptens, oligo- and polynucleotides,
lectins, receptors, carbohydrate structures, dextrans,
protein A, IgG and drugs said residue retaining the
biospecific affinity of said compound, and that residue
15 attached to G₁, G₂ or G₃ of that chelate.

9. In the method for the determination of an analyte in a
sample comprising the steps:

(a) contacting the sample with a reactant exhibiting
20 biospecific affinity towards the analyte to the
formation of a complex comprising said analyte and
said reactant, the condition and amounts of reactants
being selected so that the amount of complex formed
is a function of the amount of analyte in the sample,


25 (b) quantitatively or qualitatively measuring the
amount of complex formed by the use of a reactant
that exhibits biospecific affinity for said complex
and being labelled with an analytically detectable
group,

30 (c) relating the measured amount of the complex to
the amount of analyte in the sample,

the improvement being that the reactant labelled with the
analytically detectable group complies with a lanthanide
chelate according to any of the claims 1-8.


[received by the International Bureau on 5 April 1993 (05.04.93);
original claims 1 and 9 amended; other claims unchanged (4 pages)]

2-oxazolin-2,4-ylene:




5

3-oxazolin-2,4-ylene:




2,4-imidazolylene:




10

2-imidazolin-2,4-ylene:




3-imidazolin-2,4-ylene:




15

1,2,4-triazol-3,5-ylene:




20

1,3,4-oxadiazol-2,5-ylene:




1,2,4-oxadiazol-3,5-ylene:




25

1,3-pyrazolylene:



or

2,5-pyrrolylene:



30

and corresponding rings in which one hydrogen is
replaced with the appropriate group G_1 , G_2 and G_3 , the
same or different,

the remaining group(s) $[A_1]$, $[B]$ and $[A_2]$ is/are

2,6-pyridylene or the corresponding ring in which one hydrogen is replaced with the appropriate group G_1 , G_2 and G_3 , the same or different,

one heteroatom in each ring $[A_1]$, $[B]$ and $[A_2]$ coordinates to the same lanthanide ion so that two five-membered rings are formed in which one member is the lanthanide ion and two members are coordinating heteroatoms of different rings $[A_1]$, $[B]$ and $[A_2]$, and

e) Ch_1 and Ch_2 represent identical or different chelating groups, possibly linked together,

each of which comprises at least two heteroatoms that are coordinated to the lanthanide ion and are selected from the group consisting of oxygen and nitrogen, and at least one of the said coordinating heteroatoms in each of Ch_1 and Ch_2 forms a five- or six-membered ring together with the lanthanide ion and a coordinating heteroatom of one of $[A_1]$, $[B]$ and $[A_2]$,

the distance between each pair of heteroatoms participating in the chelation and forming the same five- or six-membered ring being two or three atoms, respectively,

f) G_1 , G_2 and G_3 , respectively, are selected from the group consisting of hydroxy, nitro, amino or lower alkyl substituted amino, lower aryl substituted amino or lower acyl substituted amino, alkyl, aryl, alkyl-aryl, arylalkyl, arylolethynyl, such as phenylethynyl, alkoxy or aryloxy groups, with the proviso alkyls contain 1-12 carbon atoms and aryls are selected from phenyl, naphthyl and pyridyl,

or a group containing aryl and alkylene parts in which the alkylene part contains from 1 to 8 carbon atoms and additionally 0 to 4 other atoms such as

oxygen, sulphur, nitrogen or phosphorus, and aryl is selected from phenyl, naphthyl and pyridyl, and each of the above mentioned groups optionally contain amino, aminooxy, carboxyl, hydroxy, aldehyde or mercapto groups or an activated form made from them such as isothiocyanato, isocyanato, diazonium, bromoacetamido, iodoacetamido, reactive esters, such as N-hydroxysuccinimido, 4-nitrophenyl and 2,4-dinitrophenyl, pyridyl-2-dithio, 4-chloro-6-ethoxy-triazon-2-ylamino or 4,6-dichlorotriazon-2-ylamino for the binding to a compound exhibiting biospecific affinity.

2. The chelate of claim 1, characterized in that [B] is 2,6-pyridylene or the corresponding group in which one hydrogen is replaced with G_2 .

3. The chelate of claim 1, characterized in that [A₁] and [A₂] are 2,6-pyridylene or the corresponding group in which one hydrogen is replaced with G_1 and G_3 , respectively.

4. The chelate of any of claims 1-3 characterized in that the lanthanide ion is selected from Eu^{3+} , Tb^{3+} , Sm^{3+} and Dy^{3+} .

5. The chelate of any of claims 1-4, characterized in that the chelating heteroatoms of Ch_1 and Ch_2 are selected from amino nitrogens (primary, secondary or tertiary) and negatively charged oxygens such as in carboxylates, phosphonates and phosphates.

6. The chelate of any of claims 1-5 characterized in that Ch_1 and Ch_2 are selected from the group consisting of $N(CH_2COO^-)_2$, $N(CH_2CH_2COO^-)_2$, $N(CH_2-PO_3^{2-})_2$ or a 2,6-dicarb-oxypiperidin-1-yl.

07. The chelate of any of claims 1-5, characterized in that
Ch₁ and Ch₂ form one or two bridges consisting of saturated
carbon, ether oxygen and nitrogen atoms, said bridges
covalently connecting [A₁] and [A₂] and said nitrogen being
5 selected from secondary or tertiary amino nitrogens.

8. The chelate of any of claims 1-7 additionally comprising
a residue of a compound exhibiting biospecific affinity
selected from the group consisting of proteins, enzymes,
10 antibodies, antigens, haptens, oligo- and polynucleotides,
lectins, receptors, carbohydrate structures, dextrans,
protein A, IgG and drugs said residue retaining the
biospecific affinity of said compound, and that residue
attached to G₁, G₂ or G₃ of that chelate.

15

9. In the method for the determination of an analyte in a
sample comprising the steps:

(a) contacting the sample with a reactant exhibiting
biospecific affinity towards the analyte resulting in
20 the formation of a complex comprising said analyte and
said reactant, the condition and amounts of reactants
being selected so that the amount of complex formed is
a function of the amount of analyte in the sample, (b)
quantitatively or qualitatively measuring the amount
25 of complex formed by the use of a reactant that
exhibits biospecific affinity for said complex and
being labelled with an analytically detectable group,
(c) relating the measured amount of the complex to the
amount of analyte in the sample,

30 the improvement being that the reactant labelled with the
analytically detectable group complies with a lanthanide
chelate according to any of the claims 1-8.

STATEMENT UNDER ARTICLE 19

The two documents cited, and marked with X, both contain 2,2':6', 2''-terpyridine moieties as an energy absorbing part of luminescent lanthanide chelates. The luminescent lanthanide chelates mentioned in our patent application are new and comprises one or two pyridines and two or one five-membered aromatic rings (totally three aromatic rings covalently coupled to each other) as an energy absorbing part. This makes these chelates chemically, physically and photochemically completely different compounds compared to previously mentioned terpyridines (see page 9, lines 10-31).

INTERNATIONAL SEARCH REPORT

International Application No PCT/FI 91/00373

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: G 01 N 33/533, C 07 D 401/14, 405/14, 413/14, 417/14, 498/22																	
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-bottom: 1px solid black;">Classification System</td> <td style="border-bottom: 1px solid black;">Classification Symbols</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom;">IPC5</td> <td style="height: 40px; vertical-align: bottom;">G 01 N; C 07 D</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched⁸</div> <p>SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	G 01 N; C 07 D											
Classification System	Classification Symbols																
IPC5	G 01 N; C 07 D																
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category *</th> <th style="width: 70%; border-bottom: 1px solid black;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 20%; border-bottom: 1px solid black;">Relevant to Claim No.¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;">WO, A1, 9000550 (WALLAC OY) 25 January 1990, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;">US, A, 4837169 (TONER) 6 June 1989, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">US, A, 4927923 (MATHIS ET AL) 22 May 1990, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">EP, A1, 0321353 (COMPAGNIE ORIS INDUSTRIE SA) 21 June 1989, see the whole document -- -----</td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	WO, A1, 9000550 (WALLAC OY) 25 January 1990, see the whole document --	1-9	X	US, A, 4837169 (TONER) 6 June 1989, see the whole document --	1-9	A	US, A, 4927923 (MATHIS ET AL) 22 May 1990, see the whole document --	1-9	A	EP, A1, 0321353 (COMPAGNIE ORIS INDUSTRIE SA) 21 June 1989, see the whole document -- -----	1-9
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
X	WO, A1, 9000550 (WALLAC OY) 25 January 1990, see the whole document --	1-9															
X	US, A, 4837169 (TONER) 6 June 1989, see the whole document --	1-9															
A	US, A, 4927923 (MATHIS ET AL) 22 May 1990, see the whole document --	1-9															
A	EP, A1, 0321353 (COMPAGNIE ORIS INDUSTRIE SA) 21 June 1989, see the whole document -- -----	1-9															
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom;">3rd July 1992</td> <td style="height: 40px; vertical-align: bottom;">1992 -07- 07</td> </tr> <tr> <td style="border-bottom: 1px solid black;">International Searching Authority</td> <td style="border-bottom: 1px solid black;">Signature of Authorized Officer</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom; text-align: center;">SWEDISH PATENT OFFICE</td> <td style="height: 40px; vertical-align: bottom; text-align: center;"> Göran Karlsson </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	3rd July 1992	1992 -07- 07	International Searching Authority	Signature of Authorized Officer	SWEDISH PATENT OFFICE	 Göran Karlsson							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
3rd July 1992	1992 -07- 07																
International Searching Authority	Signature of Authorized Officer																
SWEDISH PATENT OFFICE	 Göran Karlsson																

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers....., because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

The claims are too broadly formulated to permit a meaningful search, see Article 6. The search has been limited to the compounds considered to be most relevant.
3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/FI 91/00373**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 29/05/92. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9000550	90-01-25	EP-A- JP-T-	0403593 3500297 90-12-27 91-01-24
US-A- 4837169	89-06-06	US-A- US-A- CA-A- EP-A- JP-A- US-A- CA-A- DE-A- EP-A-B- JP-A- US-A- US-A-	4794191 4801722 1292710 0288256 1045365 4859777 1205028 3277869 0068875 58008783 4637988 4670572 88-12-27 89-01-31 91-12-03 88-10-26 89-02-17 89-08-22 86-05-27 88-02-04 83-01-05 83-01-18 87-01-20 87-06-02
US-A- 4927923	90-05-22	EP-A- FR-A-B- JP-A-	0180492 2570703 61087680 86-05-07 86-03-28 86-05-06
EP-A1- 0321353	89-06-21	AU-D- FR-A-B- JP-T- WO-A-	2908889 2624862 3502575 89/05813 89-07-19 89-06-23 91-06-13 89-06-29

THIS PAGE BLANK (USPTO)